≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Enduring personality changes

DOID Endpoint Browser PheWeb

F5_PERSOCHANGE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

519870

1. Apply sex-specific rule

None

519870

2. Check conditions

None

519870

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — F62
  • Cause of death: ICD-10 — F62

2 out of 7 registries used, show all original rules.

157

4. Check minimum number of events

None

157

5. Include endpoints

None

157

6. Filter based on genotype QC (FinnGen only)

149

Control definitions (FinnGen only)

Control exclude
F5_PERSOBEH

Extra metadata

Level in the ICD hierarchy
3
First used in FinnGen datafreeze
DF2
Parent code in ICD-10
F60-F62
Name in latin
Commutationes personalitatis persistentes non laesioni neque morbo cerebri ascribendae

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

All Female Male
Number of individuals
Whole population 1229 593 625
Only index persons 1114 557 557
Unadjusted period prevalence (%)
Whole population 0.02 0.02 0.02
Only index persons 0.02 0.02 0.02
Median age at first event (years)
Whole population 43.28 42.70 43.81
Only index persons 42.94 42.65 43.22

-FinnGen-

Key figures

All Female Male
Number of individuals 149 82 67
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 45.58 42.87 48.91

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
157
Matched controls
1570
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
F62.9
ICD-10 Finland
Enduring personality change, unspecified
+∞
60.4
54
*
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
18.7
59.6
55
44
N05AH04
ATC
quetiapine; oral
11.5
54.9
93
176
N05AX08
ATC
risperidone; systemic
15.9
54.8
56
53
N05AX12
ATC
aripiprazole; systemic
22.6
52.4
42
25
F62.0
ICD-10 Finland
Enduring personality change after catastrophic experience
+∞
50.8
46
*
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
14.7
50.8
54
54
F32.9
ICD-10 Finland
Depressive episode, unspecified
11.4
50.4
72
109
F33.2
ICD-10 Finland
Recurrent depressive disorder, current episode severe without psychotic symptoms
16.6
46.5
44
36
N05AH03
ATC
olanzapine; systemic
14.6
46.1
48
46
F62.8
ICD-10 Finland
Other enduring personality changes
+∞
45.0
41
*
T36
ICD-10 Finland
Poisoning by systemic antibiotics
20.2
42.2
35
22
N06AB04
ATC
citalopram; systemic
8.6
40.9
78
161
N06AX16
ATC
venlafaxine; oral
8.3
38.0
71
142
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
8.8
35.9
58
98
F33.9
ICD-10 Finland
Recurrent depressive disorder, unspecified
15.2
34.4
33
27
F33.10
ICD-10 Finland
Recurrent depression, moderate episode without somatic syndrome
13.0
32.8
35
34
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
9.2
32.7
48
72
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
8.3
32.7
54
93
N03AX09
ATC
lamotrigine; oral
11.6
28.1
32
34
P29
ICPC
Psychological sympt/compl other
7.9
26.8
44
74
N06AX11
ATC
mirtazapine; oral
5.8
26.7
101
370
N05CD07
ATC
temazepam; oral
7.8
26.3
43
72
N06AB06
ATC
sertraline; oral
7.0
26.1
49
95
N05BA01
ATC
diazepam; systemic, rectal
6.9
26.1
50
99
N03AG01
ATC
valproic acid; systemic, rectal
10.3
25.8
32
38
N06AB03
ATC
fluoxetine; oral
6.8
25.8
51
104
F60.9
ICD-10 Finland
Personality disorder, unspecified
295.0
25.5
25
*
N05AA02
ATC
levomepromazine; systemic
26.1
25.3
35
17
ZY010
NOMESCO Finland
Hospital outpatient
9.9
24.4
31
38
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
147.5
24.4
25
*
N03AE01
ATC
clonazepam; systemic
10.6
24.1
29
33
P76
ICPC
Depressive disorder
7.7
23.8
39
65
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
27.2
22.8
31
14
N05AB03
ATC
perphenazine; systemic, rectal
27.0
21.3
29
13
N06AA09
ATC
amitriptyline; systemic
7.3
21.0
35
59
F62.1
ICD-10 Finland
Enduring personality change after psychiatric illness
+∞
20.2
19
*
N05BA04
ATC
oxazepam; oral
4.7
20.2
74
252
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
8.0
19.4
29
43
F61.0
ICD-10 Finland
Mixed personality disorders
+∞
19.1
18
*
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
8.2
18.0
26
37
N05BA12
ATC
alprazolam; oral
6.0
17.1
35
72
F41.2
ICD-10 Finland
Mixed anxiety and depressive disorder
5.2
17.0
43
107
F60.31
ICD-10 Finland
Emotionally unstable personality disorder, borderline condition
189.3
16.8
17
*
F60.3
ICD-10 Finland
Emotionally unstable personality disorder
189.3
16.8
17
*
N06AX21
ATC
duloxetine; oral
4.9
16.5
45
119
SPAT1240
SPAT
Therapeutic discussion
5.2
16.5
40
96
N05CF01
ATC
zopiclone; oral
4.0
16.4
77
305
F29
ICD-10 Finland
Unspecified nonorganic psychosis
13.4
16.1
28
25
N03AX16
ATC
[U] pregabalin
4.2
16.0
59
197
N05AF03
ATC
chlorprothixene; systemic
20.5
15.7
23
13
F43.1
ICD-10 Finland
Post-traumatic stress disorder
12.8
15.2
27
25
Z2446
NOMESCO Finland
Social worker
6.6
15.2
27
48
N06AX03
ATC
mianserin; oral
12.7
14.7
26
24
P74
ICPC
Anxiety disorder/anxiety state
6.6
14.2
25
44
F34.1
ICD-10 Finland
Dysthymia
11.7
14.1
26
26
N03AX12
ATC
[U] gabapentin; oral
4.1
13.7
47
147
F32.11
ICD-10 Finland
Moderate depressive episode with somatic syndrome
14.8
13.4
22
17
ZXE06
NOMESCO Finland
Procedure duration 50 to 59 minutes
6.4
13.3
24
43
N06AB05
ATC
paroxetine; oral
6.6
13.2
23
40
L28
ICPC
Limited function/disability (L)
4.2
13.0
42
125
J18.9
ICD-10 Finland
Pneumonia, unspecified
3.7
12.9
56
205
N05BA06
ATC
lorazepam; systemic, sublingual
11.5
12.5
23
23
F32.1
ICD-10 Finland
Moderate depressive episode
5.1
12.3
29
67
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
4.8
12.1
31
77
N06AX12
ATC
bupropion; oral
5.2
12.0
27
60
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
32.9
11.9
15
5
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
9.6
11.8
24
29
F33.30
ICD-10 Finland
Recurrent depression, severe episode without somatic syndrome
129.1
11.6
12
*
F60.5
ICD-10 Finland
Anankastic personality disorder
46.9
11.1
13
*
ZXE02
NOMESCO Finland
Procedure duration 10 to 19 minutes
9.1
11.1
23
29
F32.8
ICD-10 Finland
Other depressive episodes
23.5
10.9
15
7
ZXE13
NOMESCO Finland
Procedure duration 90 to 119 minutes
9.0
10.5
22
28
N05AD01
ATC
haloperidol; systemic
14.5
10.4
17
13
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.1
10.4
24
54
N05AN01
ATC
lithium; oral
11.2
10.3
19
19
IGY02
NOMESCO Finland
Psychiatric monitoring contact
9.1
10.2
21
26
F31.9
ICD-10 Finland
Bipolar affective disorder, unspecified
13.4
10.1
17
14
IGY99
NOMESCO Finland
Other psychiatric treatment contact
10.6
10.1
19
20
F41.1
ICD-10 Finland
Generalized anxiety disorder
4.9
10.0
24
56
A01
ICPC
Pain general/multiple sites
4.0
10.0
32
94
F45.4
ICD-10 Finland
Persistent somatoform pain disorder
14.7
9.9
16
12
P01
ICPC
Feeling anxious/nervous/tense
3.4
9.9
43
155
SPAT1260
SPAT
Consultation of another employee
3.5
9.7
41
145
N06CA01
ATC
amitriptyline and psycholeptics; systemic
4.4
9.7
27
71
WZC00, ,
SPAT
3.7
9.6
36
118
ICC04
NOMESCO Finland
Psychiatric treatment plan, permanent discontinuation
10.5
9.6
18
19
N04AA02
ATC
biperiden; systemic
23.4
9.5
13
6
F61
ICD-10 Finland
Mixed and other personality disorders
+∞
9.5
9
*
F40.1
ICD-10 Finland
Social phobias
12.6
9.3
16
14
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
8.5
9.0
19
25
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
3.8
8.9
31
96
N06AA12
ATC
doxepin; systemic
7.2
8.8
21
33
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
9.9
8.8
17
19
F20.9
ICD-10 Finland
Schizophrenia, unspecified
12.6
8.8
15
13
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
7.5
8.7
20
30
L03
ICPC
Low back symptom/complaint
2.8
8.6
64
311
SPAT1307
SPAT
Psychosocial counselling and guidance
5.1
8.6
19
41
F31.4
ICD-10 Finland
Bipolar affective disorder, current episode severe depression without psychotic symptoms
29.3
8.6
11
*
A06AD11
ATC
lactulose; oral
3.8
8.6
30
93
ZXE15
NOMESCO Finland
Procedure duration 120 to 149 minutes
13.8
8.6
14
11
N06AB10
ATC
escitalopram; oral
2.9
8.5
53
234
C03CA01
ATC
furosemide; systemic
3.0
8.5
46
188
N06AX26
ATC
vortioxetine; oral
4.2
8.4
24
64
N06AG02
ATC
moclobemide; oral
7.6
8.4
19
28
F99
ICD-10 Finland
Mental disorder, not otherwise specified
12.7
8.3
14
12
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
4.1
8.2
25
70
X44
ICD-10 Finland
Accidental poisoning by and exposure to other and unspecified drugs, medicaments and biological substances
18.4
8.2
12
7
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.9
8.1
26
76
Z76.8
ICD-10 Finland
Persons encountering health services in other specified circumstances
6.6
8.0
20
34
R02
ICPC
Shortness of breath/dyspnoea
3.5
7.9
30
98
R53
ICD-10 Finland
Malaise and fatigue
2.7
7.8
55
258
N05AB01
ATC
dixyrazine; systemic
47.4
7.8
9
*
J01FF01
ATC
clindamycin; systemic
2.7
7.7
57
274
N07BB01
ATC
disulfiram; oral
7.1
7.7
18
28
P03
ICPC
Feeling depressed
3.4
7.6
31
106
F33.11
ICD-10 Finland
Recurrent depression, moderate episode of somatic syndrome
9.1
7.5
15
18
N03AF01
ATC
carbamazepine; oral, rectal
6.9
7.5
18
29
F60.8
ICD-10 Finland
Other specific personality disorders
83.9
7.5
8
*
ZYC01
NOMESCO Finland
Remote contact by phone
4.3
7.2
20
52
N05AL01
ATC
sulpiride; systemic
21.2
7.2
10
5
N06AA04
ATC
clomipramine; systemic
21.2
7.2
10
5
SPAT1263
SPAT
Sampling
2.5
7.2
74
415
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
4.4
7.1
19
48
Z04.8
ICD-10 Finland
Examination and observation for other specified reasons
3.2
7.1
32
117
N02BF02
ATC
pregabalin; oral
4.2
7.1
20
53
SPAT1250
SPAT
Comprehensive monitoring of chronic illness
2.9
7.0
41
173
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
6.2
7.0
18
32
R11
ICD-10 Finland
Nausea and vomiting
3.8
7.0
23
68
J45.9
ICD-10 Finland
Asthma, unspecified
2.9
7.0
40
167
R52.2
ICD-10 Finland
Other chronic pain
6.4
6.8
17
29
ICB01, ,
SPAT
41.9
6.8
8
*
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
3.6
6.7
24
75
Z76.9
ICD-10 Finland
Person encountering health services in unspecified circumstances
3.4
6.7
26
86
Z2445
NOMESCO Finland
Psychologist
5.8
6.7
18
34
P99
ICPC
Psychological disorders other
7.4
6.7
15
22
M54.4
ICD-10 Finland
Lumbago with sciatica
2.7
6.7
43
191
IBZ01
NOMESCO Finland
Profession-specific psychiatric evaluation
10.7
6.7
12
12
Z3231
NOMESCO Finland
Registered nurse
2.5
6.7
54
269
M54.5
ICD-10 Finland
Low back pain
2.4
6.6
74
426
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.6
6.6
51
248
F41.8
ICD-10 Finland
Other specified anxiety disorders
6.5
6.5
16
27
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
2.4
6.5
73
421
F31.30
ICD-10 Finland
Bipolar disorder Depressive episode without somatic syndrome
15.1
6.5
10
7
ICB03, ,
SPAT
72.7
6.5
7
*
F21
ICD-10 Finland
Schizotypal disorder
72.7
6.5
7
*
M03BA52
ATC
carisoprodol, combinations excl. psycholeptics; oral
11.7
6.4
11
10
N05BE01
ATC
buspirone; oral
6.8
6.3
15
24
SPAT1219
SPAT
Assessment of need for vocational rehabilitation
+∞
6.3
6
*
F60.2
ICD-10 Finland
Dissocial personality disorder
+∞
6.3
6
*
N05CF02
ATC
zolpidem; oral
2.7
6.3
39
170
ZXY51
NOMESCO Finland
2-person team, doctor-nurse
9.2
6.2
12
14
F43.9
ICD-10 Finland
Reaction to severe stress, unspecified
6.5
6.2
15
25
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
3.7
6.1
20
59
SPAT1149
SPAT
Suture or treatment of traumatic wound
3.3
6.1
25
86
S06.0
ICD-10 Finland
Concussion
3.3
6.1
25
86

TimeCodeWAS

↥

TODO / Current known limitations:

  • Only showing the top 300 codes, because showing all (sometimes 20k) makes the page too slow.
  • Legend / how to read the glyphs.
  • Show details (e.g. Fisher or Chi-square test, LR+, etc.) when clicking on a row.
  • Explanation on the underlying data / how the TimeCodeWAS is done (e.g. matched cases / controls, eligibility).
  • Download CSV.
  • No filters and sorters.
  • Limited amount of endpoints (~400) having TimeCodeWAS data.
  • Cross-links to Risteys lab test pages for lab test codes.
OMOP concept
ln(OR)
%cases with code / %controls with code
2×2 table
Psychiatry
26 [38004469]
3.6e+00
4.4e+00
4.0e+00
1.0e+50
4.4e+00
4.5e+00
3.5e+00
cases:57.42%
controls:3.61%
cases:59.62%
controls:1.86%
cases:38.46%
controls:1.15%
cases:75.64%
controls:0.00%
cases:42.95%
controls:0.96%
cases:66.03%
controls:2.02%
cases:64.58%
controls:5.22%
89
56
66
1494
93
29
63
1531
60
18
96
1542
118
0
38
1560
67
15
89
1544
103
31
53
1506
93
74
51
1343
quetiapine; oral
N05AH04 [21604544]
2.7e+00
2.7e+00
2.9e+00
—
2.5e+00
3.0e+00
2.6e+00
cases:23.87%
controls:2.00%
cases:16.03%
controls:1.22%
cases:8.33%
controls:0.51%
—
—
cases:5.13%
controls:0.45%
cases:20.51%
controls:1.24%
cases:25.00%
controls:2.40%
37
31
118
1519
25
19
131
1541
13
8
143
1552
—
8
7
148
1552
32
19
124
1518
36
34
108
1383
Mixed anxiety and depressive disorder
F41.2 [45566845]
2.5e+00
2.3e+00
—
1.0e+50
2.5e+00
2.7e+00
1.8e+00
cases:10.32%
controls:0.90%
cases:5.13%
controls:0.51%
—
—
cases:5.13%
controls:0.00%
cases:3.85%
controls:0.32%
cases:8.33%
controls:0.59%
cases:9.03%
controls:1.62%
16
14
139
1536
8
8
148
1552
—
8
0
148
1560
6
5
150
1554
13
9
143
1528
13
23
131
1394
pregabalin; oral
N02BF02 [955152]
1.7e+00
1.9e+00
2.5e+00
—
2.2e+00
1.8e+00
1.6e+00
cases:11.61%
controls:2.32%
cases:8.33%
controls:1.28%
cases:3.85%
controls:0.32%
—
—
cases:4.49%
controls:0.51%
cases:8.33%
controls:1.50%
cases:13.19%
controls:3.03%
18
36
137
1514
13
20
143
1540
6
5
150
1555
—
7
8
149
1551
13
23
143
1514
19
43
125
1374
General psychiatric examination, not elsewhere classified
Z00.4 [45605094]
3.4e+00
3.3e+00
—
—
—
2.3e+00
2.0e+00
cases:9.03%
controls:0.32%
cases:7.69%
controls:0.32%
—
—
—
—
—
—
cases:5.13%
controls:0.52%
cases:7.64%
controls:1.13%
14
5
141
1545
12
5
144
1555
—
—
—
8
8
148
1529
11
16
133
1401
venlafaxine; oral
N06AX16 [21604745]
2.9e+00
2.8e+00
—
—
—
2.8e+00
2.4e+00
cases:17.42%
controls:1.10%
cases:11.54%
controls:0.77%
—
—
—
—
—
—
cases:12.18%
controls:0.85%
cases:19.44%
controls:2.12%
27
17
128
1533
18
12
138
1548
—
—
—
19
13
137
1524
28
30
116
1387
oxazepam; oral
N05BA04 [21604569]
2.3e+00
2.2e+00
1.9e+00
—
2.2e+00
1.8e+00
1.7e+00
cases:22.58%
controls:2.90%
cases:12.82%
controls:1.67%
cases:3.21%
controls:0.51%
—
—
cases:5.13%
controls:0.58%
cases:12.18%
controls:2.21%
cases:23.61%
controls:5.29%
35
45
120
1505
20
26
136
1534
5
8
151
1552
—
8
9
148
1550
19
34
137
1503
34
75
110
1342
Emergency Room Visit
ER [9203]
1.2e+00
1.4e+00
2.4e+00
—
2.4e+00
1.5e+00
1.2e+00
cases:56.13%
controls:27.68%
cases:33.33%
controls:11.03%
cases:13.46%
controls:1.35%
—
—
cases:8.33%
controls:0.83%
cases:30.77%
controls:8.91%
cases:58.33%
controls:29.15%
87
429
68
1121
52
172
104
1388
21
21
135
1539
—
13
13
143
1546
48
137
108
1400
84
413
60
1004
zopiclone; oral
N05CF01 [21604654]
2.1e+00
1.8e+00
2.8e+00
—
1.4e+00
1.8e+00
1.5e+00
cases:24.52%
controls:3.74%
cases:15.38%
controls:2.95%
cases:7.05%
controls:0.45%
—
—
cases:3.21%
controls:0.83%
cases:13.46%
controls:2.41%
cases:21.53%
controls:5.50%
38
58
117
1492
24
46
132
1514
11
7
145
1553
—
5
13
151
1546
21
37
135
1500
31
78
113
1339
alprazolam; oral
N05BA12 [21604577]
2.4e+00
2.9e+00
—
—
—
2.5e+00
2.3e+00
cases:9.68%
controls:0.97%
cases:5.77%
controls:0.32%
—
—
—
—
—
—
cases:5.77%
controls:0.52%
cases:6.94%
controls:0.78%
15
15
140
1535
9
5
147
1555
—
—
—
9
8
147
1529
10
11
134
1406
Outpatient Visit
OP [9202]
1.3e+00
1.6e+00
2.0e+00
—
2.1e+00
1.7e+00
1.0e+00
cases:83.87%
controls:57.81%
cases:75.00%
controls:37.31%
cases:41.67%
controls:8.85%
—
—
cases:42.95%
controls:8.72%
cases:76.92%
controls:37.93%
cases:87.50%
controls:71.84%
130
896
25
654
117
582
39
978
65
138
91
1422
—
67
136
89
1423
120
583
36
954
126
1018
18
399
sertraline; oral
N06AB06 [21604714]
2.2e+00
2.8e+00
—
—
—
2.4e+00
2.3e+00
cases:10.97%
controls:1.35%
cases:9.62%
controls:0.64%
—
—
—
—
—
—
cases:8.33%
controls:0.85%
cases:11.11%
controls:1.27%
17
21
138
1529
15
10
141
1550
—
—
—
13
13
143
1524
16
18
128
1399
Severe depressive episode without psychotic symptoms
F32.2 [45557202]
2.9e+00
—
—
1.0e+50
—
3.7e+00
2.9e+00
cases:12.90%
controls:0.77%
—
—
—
—
cases:6.41%
controls:0.00%
—
—
cases:12.18%
controls:0.33%
cases:13.89%
controls:0.85%
20
12
135
1538
—
—
10
0
146
1560
—
19
5
137
1532
20
12
124
1405
Inpatient Hospital
21 [8717]
1.3e+00
1.6e+00
1.8e+00
—
1.9e+00
1.7e+00
9.4e-01
cases:56.13%
controls:26.77%
cases:36.54%
controls:10.32%
cases:9.62%
controls:1.67%
—
—
cases:8.33%
controls:1.35%
cases:34.62%
controls:8.59%
cases:46.53%
controls:25.34%
87
415
68
1135
57
161
99
1399
15
26
141
1534
—
13
21
143
1538
54
132
102
1405
67
359
77
1058
olanzapine; oral, parenteral
N05AH03 [21604543]
2.9e+00
—
—
—
—
3.1e+00
2.9e+00
cases:5.81%
controls:0.32%
—
—
—
—
—
—
—
—
cases:7.69%
controls:0.39%
cases:13.89%
controls:0.85%
9
5
146
1545
—
—
—
—
12
6
144
1531
20
12
124
1405
Anxiety disorder, unspecified
F41.9 [45542849]
3.5e+00
3.3e+00
—
—
—
—
2.2e+00
cases:10.97%
controls:0.39%
cases:7.69%
controls:0.32%
—
—
—
—
—
—
—
—
cases:8.33%
controls:0.99%
17
6
138
1544
12
5
144
1555
—
—
—
—
12
14
132
1403
diazepam; oral, parenteral, rectal
N05BA01 [21604566]
2.2e+00
2.3e+00
—
—
—
2.5e+00
1.9e+00
cases:14.19%
controls:1.81%
cases:7.05%
controls:0.77%
—
—
—
—
—
—
cases:7.69%
controls:0.65%
cases:11.81%
controls:1.98%
22
28
133
1522
11
12
145
1548
—
—
—
12
10
144
1527
17
28
127
1389
Neurology
13 [38004458]
1.7e+00
2.0e+00
2.2e+00
1.0e+50
—
1.3e+00
1.4e+00
cases:29.68%
controls:6.97%
cases:18.59%
controls:3.08%
cases:4.49%
controls:0.51%
cases:4.49%
controls:0.00%
—
—
cases:14.10%
controls:4.10%
cases:27.78%
controls:8.75%
46
108
109
1442
29
48
127
1512
7
8
149
1552
7
0
149
1560
—
22
63
134
1474
40
124
104
1293
Recurrent depression, moderate episode without somatic syndrome
F33.10 [2000501984]
2.7e+00
2.7e+00
—
—
1.0e+50
—
2.6e+00
cases:9.03%
controls:0.65%
cases:4.49%
controls:0.32%
—
—
—
—
cases:3.21%
controls:0.00%
—
—
cases:9.03%
controls:0.71%
14
10
141
1540
7
5
149
1555
—
—
5
0
151
1559
—
13
10
131
1407
gabapentin; oral
N02BF01 [955005]
2.1e+00
1.8e+00
—
—
—
2.2e+00
1.7e+00
cases:10.32%
controls:1.42%
cases:4.49%
controls:0.77%
—
—
—
—
—
—
cases:6.41%
controls:0.78%
cases:12.50%
controls:2.54%
16
22
139
1528
7
12
149
1548
—
—
—
10
12
146
1525
18
36
126
1381
Pharmacy visit
OMOP4822462 [581458]
1.3e+00
1.4e+00
1.4e+00
1.9e+00
1.1e+00
1.9e+00
1.5e+00
cases:96.77%
controls:89.29%
cases:92.31%
controls:75.13%
cases:64.74%
controls:31.22%
cases:8.33%
controls:1.35%
cases:58.97%
controls:32.01%
cases:95.51%
controls:75.21%
cases:98.61%
controls:94.00%
150
1384
5
166
144
1172
12
388
101
487
55
1073
13
21
143
1539
92
499
64
1060
149
1156
7
381
142
1332
2
85
duloxetine; oral
N06AX21 [21604749]
2.7e+00
2.7e+00
—
—
—
2.3e+00
1.3e+00
cases:11.61%
controls:0.90%
cases:6.41%
controls:0.45%
—
—
—
—
—
—
cases:5.13%
controls:0.52%
cases:6.25%
controls:1.83%
18
14
137
1536
10
7
146
1553
—
—
—
8
8
148
1529
9
26
135
1391
mirtazapine; oral
N06AX11 [21604740]
2.2e+00
2.1e+00
—
—
2.0e+00
2.2e+00
1.1e+00
cases:24.52%
controls:3.48%
cases:11.54%
controls:1.60%
—
—
—
—
cases:3.21%
controls:0.45%
cases:14.10%
controls:1.76%
cases:15.97%
controls:5.93%
38
54
117
1496
18
25
138
1535
—
—
5
7
151
1552
22
27
134
1510
23
84
121
1333
Depressive episode, unspecified
F32.9 [45571760]
2.5e+00
—
—
1.0e+50
1.0e+50
3.0e+00
2.1e+00
cases:12.90%
controls:1.23%
—
—
—
—
cases:3.85%
controls:0.00%
cases:3.21%
controls:0.00%
cases:9.62%
controls:0.52%
cases:10.42%
controls:1.41%
20
19
135
1531
—
—
6
0
150
1560
5
0
151
1559
15
8
141
1529
15
20
129
1397
clonazepam; oral, parenteral
N03AE01 [21604415]
2.4e+00
2.9e+00
—
—
—
—
2.1e+00
cases:6.45%
controls:0.65%
cases:6.41%
controls:0.38%
—
—
—
—
—
—
—
—
cases:7.64%
controls:0.99%
10
10
145
1540
10
6
146
1554
—
—
—
—
11
14
133
1403
temazepam; oral
N05CD07 [21604642]
1.9e+00
2.0e+00
2.1e+00
—
—
1.7e+00
1.7e+00
cases:14.19%
controls:2.32%
cases:10.90%
controls:1.60%
cases:3.21%
controls:0.38%
—
—
—
—
cases:7.05%
controls:1.37%
cases:13.89%
controls:2.89%
22
36
133
1514
17
25
139
1535
5
6
151
1554
—
—
11
21
145
1516
20
41
124
1376
amitriptyline; oral, parenteral
N06AA09 [21604696]
1.7e+00
1.9e+00
—
—
2.1e+00
1.6e+00
1.6e+00
cases:14.19%
controls:2.97%
cases:8.97%
controls:1.41%
—
—
—
—
cases:3.21%
controls:0.38%
cases:6.41%
controls:1.30%
cases:13.89%
controls:3.25%
22
46
133
1504
14
22
142
1538
—
—
5
6
151
1553
10
20
146
1517
20
46
124
1371
valproic acid; oral, parenteral, rectal
N03AG01 [21604422]
2.2e+00
2.0e+00
—
—
—
1.8e+00
2.4e+00
cases:5.81%
controls:0.71%
cases:3.85%
controls:0.51%
—
—
—
—
—
—
cases:3.85%
controls:0.65%
cases:8.33%
controls:0.78%
9
11
146
1539
6
8
150
1552
—
—
—
6
10
150
1527
12
11
132
1406
Depressive disorder
P76 [2002000870]
2.0e+00
—
—
—
—
2.7e+00
1.8e+00
cases:5.16%
controls:0.71%
—
—
—
—
—
—
—
—
cases:4.49%
controls:0.33%
cases:5.56%
controls:0.92%
8
11
147
1539
—
—
—
—
7
5
149
1532
8
13
136
1404
fluoxetine; oral
N06AB03 [21604711]
2.4e+00
1.5e+00
—
—
—
2.3e+00
1.7e+00
cases:13.55%
controls:1.35%
cases:3.21%
controls:0.77%
—
—
—
—
—
—
cases:3.85%
controls:0.39%
cases:6.94%
controls:1.34%
21
21
134
1529
5
12
151
1548
—
—
—
6
6
150
1531
10
19
134
1398
Recurrent depressive disorder, current episode severe without psychotic symptoms
F33.2 [45547705]
2.8e+00
1.0e+50
—
1.0e+50
—
—
3.5e+00
cases:7.10%
controls:0.45%
cases:6.41%
controls:0.00%
—
—
cases:7.05%
controls:0.00%
—
—
—
—
cases:12.50%
controls:0.42%
11
7
144
1543
10
0
146
1560
—
11
0
145
1560
—
—
18
6
126
1411
amitriptyline and psycholeptics
N06CA01 [21604789]
1.9e+00
2.3e+00
—
—
—
2.0e+00
—
cases:7.74%
controls:1.23%
cases:4.49%
controls:0.45%
—
—
—
—
—
—
cases:3.85%
controls:0.52%
—
—
12
19
143
1531
7
7
149
1553
—
—
—
6
8
150
1529
—
Case Management Agency
251B00000X [38004193]
4.0e-01
5.4e-01
8.0e-01
3.9e+00
8.5e-01
6.7e-01
5.4e-01
cases:54.19%
controls:44.32%
cases:50.64%
controls:37.31%
cases:26.28%
controls:13.85%
cases:16.67%
controls:0.38%
cases:25.00%
controls:12.44%
cases:57.69%
controls:41.18%
cases:73.61%
controls:61.96%
84
687
71
863
79
582
77
978
41
216
115
1344
26
6
130
1554
39
194
117
1365
90
633
66
904
106
878
38
539
Internal Medicine
11 [38004456]
1.2e+00
1.2e+00
1.7e+00
—
1.5e+00
1.1e+00
9.8e-01
cases:36.77%
controls:15.23%
cases:19.87%
controls:6.73%
cases:6.41%
controls:1.22%
—
—
cases:5.13%
controls:1.15%
cases:17.31%
controls:6.31%
cases:34.03%
controls:16.16%
57
236
98
1314
31
105
125
1455
10
19
146
1541
—
8
18
148
1541
27
97
129
1440
49
229
95
1188
citalopram; oral, parenteral
N06AB04 [21604712]
2.2e+00
2.1e+00
—
—
—
1.9e+00
1.2e+00
cases:21.29%
controls:2.84%
cases:9.62%
controls:1.28%
—
—
—
—
—
—
cases:7.05%
controls:1.17%
cases:8.33%
controls:2.61%
33
44
122
1506
15
20
141
1540
—
—
—
11
18
145
1519
12
37
132
1380
General Practice
1 [38004446]
1.4e+00
2.1e+00
2.3e+00
1.0e+50
—
1.5e+00
1.2e+00
cases:25.16%
controls:7.68%
cases:19.23%
controls:2.88%
cases:3.21%
controls:0.32%
cases:5.77%
controls:0.00%
—
—
cases:14.10%
controls:3.58%
cases:25.00%
controls:9.24%
39
119
116
1431
30
45
126
1515
5
5
151
1555
9
0
147
1560
—
22
55
134
1482
36
131
108
1286
Physical Medicine And Rehabilitation
25 [38004468]
1.4e+00
1.7e+00
—
1.0e+50
—
1.5e+00
1.3e+00
cases:19.35%
controls:5.35%
cases:10.90%
controls:2.12%
—
—
cases:3.21%
controls:0.00%
—
—
cases:6.41%
controls:1.56%
cases:18.06%
controls:5.65%
30
83
125
1467
17
33
139
1527
—
5
0
151
1560
—
10
24
146
1513
26
80
118
1337
Moderate depressive episode without somatic syndrome
F32.10 [2000501980]
3.1e+00
—
—
1.0e+50
—
—
2.8e+00
cases:11.61%
controls:0.58%
—
—
—
—
cases:4.49%
controls:0.00%
—
—
—
—
cases:11.11%
controls:0.78%
18
9
137
1541
—
—
7
0
149
1560
—
—
16
11
128
1406
risperidone; oral, parenteral
N05AX08 [21604559]
1.6e+00
1.9e+00
—
—
—
2.9e+00
2.9e+00
cases:3.87%
controls:0.77%
cases:3.21%
controls:0.51%
—
—
—
—
—
—
cases:9.62%
controls:0.59%
cases:11.81%
controls:0.71%
6
12
149
1538
5
8
151
1552
—
—
—
15
9
141
1528
17
10
127
1407
Hospital outpatient
ZY010 [2001311599]
2.1e+00
2.5e+00
—
—
—
—
3.1e+00
cases:3.23%
controls:0.39%
cases:4.49%
controls:0.38%
—
—
—
—
—
—
—
—
cases:7.64%
controls:0.35%
5
6
150
1544
7
6
149
1554
—
—
—
—
11
5
133
1412
Office Visit
OMOP4822458 [581477]
1.3e+00
1.9e+00
—
1.0e+50
—
1.4e+00
9.9e-01
cases:21.94%
controls:7.42%
cases:12.82%
controls:2.18%
—
—
cases:3.21%
controls:0.00%
—
—
cases:8.33%
controls:2.15%
cases:18.06%
controls:7.55%
34
115
121
1435
20
34
136
1526
—
5
0
151
1560
—
13
33
143
1504
26
107
118
1310
aripiprazole; oral, parenteral
N05AX12 [21604562]
—
—
—
—
—
3.0e+00
2.5e+00
—
—
—
—
—
—
—
—
—
—
cases:7.05%
controls:0.39%
cases:9.03%
controls:0.78%
—
—
—
—
—
11
6
145
1531
13
11
131
1406
Asthma, unspecified
J45.9 [45562456]
1.5e+00
1.6e+00
—
—
—
2.2e+00
1.8e+00
cases:5.81%
controls:1.35%
cases:3.85%
controls:0.77%
—
—
—
—
—
—
cases:4.49%
controls:0.52%
cases:10.42%
controls:1.98%
9
21
146
1529
6
12
150
1548
—
—
—
7
8
149
1529
15
28
129
1389
Procedure duration 60 to 89 minutes
ZXE11 [2001311402]
—
—
—
—
—
2.5e+00
2.9e+00
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.33%
cases:6.25%
controls:0.35%
—
—
—
—
—
6
5
150
1532
9
5
135
1412
Child and Adolescent Psychiatry
OMOP4821986 [45756756]
2.3e+00
3.1e+00
—
—
—
2.0e+00
—
cases:3.87%
controls:0.39%
cases:6.41%
controls:0.32%
—
—
—
—
—
—
cases:3.21%
controls:0.46%
—
—
6
6
149
1544
10
5
146
1555
—
—
—
5
7
151
1530
—
Emergency Medicine
93 [38004510]
6.2e-01
1.1e+00
2.0e+00
—
—
1.3e+00
9.2e-01
cases:10.32%
controls:5.81%
cases:9.62%
controls:3.40%
cases:3.85%
controls:0.51%
—
—
—
—
cases:10.26%
controls:3.06%
cases:26.39%
controls:12.49%
16
90
139
1460
15
53
141
1507
6
8
150
1552
—
—
16
47
140
1490
38
177
106
1240
Upper gastrointestinal surgery
106 [44777669]
1.2e+00
1.5e+00
—
—
—
1.4e+00
1.0e+00
cases:12.90%
controls:4.32%
cases:8.97%
controls:2.18%
—
—
—
—
—
—
cases:7.69%
controls:1.95%
cases:17.36%
controls:7.06%
20
67
135
1483
14
34
142
1526
—
—
—
12
30
144
1507
25
100
119
1317
lorazepam; oral, parenteral, sublingual
N05BA06 [21604571]
2.8e+00
—
—
—
—
—
2.3e+00
cases:5.81%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:0.71%
9
6
146
1544
—
—
—
—
—
10
10
134
1407
furosemide; oral, parenteral
C03CA01 [21601518]
1.9e+00
1.2e+00
—
—
—
1.6e+00
1.3e+00
cases:7.74%
controls:1.23%
cases:4.49%
controls:1.35%
—
—
—
—
—
—
cases:5.77%
controls:1.17%
cases:10.42%
controls:3.18%
12
19
143
1531
7
21
149
1539
—
—
—
9
18
147
1519
15
45
129
1372
Urology
34 [38004474]
1.4e+00
1.4e+00
-1.0e+50
—
—
2.1e+00
1.2e+00
cases:9.68%
controls:2.45%
cases:3.21%
controls:0.83%
cases:0.00%
controls:0.38%
—
—
—
—
cases:7.05%
controls:0.91%
cases:11.81%
controls:3.95%
15
38
140
1512
5
13
151
1547
0
6
156
1554
—
—
11
14
145
1523
17
56
127
1361
tramadol; oral, parenteral, rectal
N02AX02 [21604298]
1.6e+00
1.8e+00
2.3e+00
—
—
1.3e+00
1.3e+00
cases:21.94%
controls:5.23%
cases:10.26%
controls:1.92%
cases:3.21%
controls:0.32%
—
—
—
—
cases:6.41%
controls:1.76%
cases:18.75%
controls:5.93%
34
81
121
1469
16
30
140
1530
5
5
151
1555
—
—
10
27
146
1510
27
84
117
1333
paroxetine; oral
N06AB05 [21604713]
1.8e+00
2.3e+00
—
—
—
2.3e+00
1.4e+00
cases:3.87%
controls:0.65%
cases:3.85%
controls:0.38%
—
—
—
—
—
—
cases:4.49%
controls:0.46%
cases:3.47%
controls:0.92%
6
10
149
1540
6
6
150
1554
—
—
—
7
7
149
1530
5
13
139
1404
Other and unspecified symptoms and signs involving cognitive functions and awareness
R41.8 [45534452]
2.1e+00
—
—
—
—
—
2.3e+00
cases:4.52%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.49%
7
9
148
1541
—
—
—
—
—
7
7
137
1410
lansoprazole; oral
A02BC03 [21600098]
1.1e+00
1.1e+00
-1.0e+50
—
—
1.7e+00
1.4e+00
cases:9.68%
controls:3.35%
cases:4.49%
controls:1.54%
cases:0.00%
controls:0.38%
—
—
—
—
cases:7.69%
controls:1.50%
cases:9.72%
controls:2.61%
15
52
140
1498
7
24
149
1536
0
6
156
1554
—
—
12
23
144
1514
14
37
130
1380
Anesthesiology Critical Care Medicine
OMOP4821991 [45756751]
1.9e+00
—
—
—
—
—
2.3e+00
cases:5.16%
controls:0.77%
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:0.85%
8
12
147
1538
—
—
—
—
—
11
12
133
1405
Generalized anxiety disorder
F41.1 [45571764]
—
—
—
1.0e+50
—
2.2e+00
2.0e+00
—
—
—
—
—
—
cases:3.85%
controls:0.00%
—
—
cases:3.85%
controls:0.46%
cases:4.86%
controls:0.71%
—
—
—
6
0
150
1560
—
6
7
150
1530
7
10
137
1407
pantoprazole; oral, parenteral
A02BC02 [21600097]
1.1e+00
1.2e+00
1.7e+00
—
—
1.1e+00
7.5e-01
cases:21.29%
controls:8.45%
cases:13.46%
controls:4.42%
cases:3.85%
controls:0.71%
—
—
—
—
cases:12.18%
controls:4.55%
cases:26.39%
controls:14.54%
33
131
122
1419
21
69
135
1491
6
11
150
1549
—
—
19
70
137
1467
38
206
106
1211
levothyroxine sodium; oral, parenteral
H03AA01 [21602754]
1.1e+00
1.0e+00
6.7e-01
—
7.9e-01
9.4e-01
9.3e-01
cases:14.19%
controls:5.42%
cases:13.46%
controls:5.32%
cases:3.21%
controls:1.67%
—
—
cases:3.21%
controls:1.48%
cases:13.46%
controls:5.73%
cases:16.67%
controls:7.34%
22
84
133
1466
21
83
135
1477
5
26
151
1534
—
5
23
151
1536
21
88
135
1449
24
104
120
1313
oxycodone; oral, parenteral
N02AA05 [21604260]
2.2e+00
—
—
—
—
—
1.7e+00
cases:4.52%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:1.06%
7
8
148
1542
—
—
—
—
—
8
15
136
1402
Outpatient Hospital
22 [8756]
8.9e-01
1.2e+00
9.9e-01
—
—
1.1e+00
7.2e-01
cases:36.77%
controls:19.29%
cases:19.87%
controls:7.18%
cases:3.21%
controls:1.22%
—
—
—
—
cases:17.31%
controls:6.44%
cases:33.33%
controls:19.62%
57
299
98
1251
31
112
125
1448
5
19
151
1541
—
—
27
99
129
1438
48
278
96
1139
Implementation of physical therapy rehabilitation plan
SPAT1223 [2001700324]
1.6e+00
1.4e+00
—
—
—
2.2e+00
1.0e+00
cases:9.03%
controls:2.00%
cases:3.21%
controls:0.83%
—
—
—
—
—
—
cases:5.77%
controls:0.65%
cases:6.94%
controls:2.61%
14
31
141
1519
5
13
151
1547
—
—
—
9
10
147
1527
10
37
134
1380
Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma
1920-8 [3013721]
1.3e+00
6.2e-01
—
—
—
1.4e+00
1.1e+00
cases:9.68%
controls:2.84%
cases:3.85%
controls:2.12%
—
—
—
—
—
—
cases:7.69%
controls:2.08%
cases:14.58%
controls:5.22%
15
44
140
1506
6
33
150
1527
—
—
—
12
32
144
1505
21
74
123
1343
Holo-transcobalamin II [Moles/volume] in Serum
72160-5 [43054903]
1.3e+00
1.5e+00
—
—
—
9.6e-01
9.2e-01
cases:7.74%
controls:2.26%
cases:5.77%
controls:1.28%
—
—
—
—
—
—
cases:5.13%
controls:2.02%
cases:13.19%
controls:5.72%
12
35
143
1515
9
20
147
1540
—
—
—
8
31
148
1506
19
81
125
1336
bupropion; oral
N06AX12 [21604741]
2.0e+00
—
—
—
—
—
1.8e+00
cases:4.52%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.99%
7
10
148
1540
—
—
—
—
—
8
14
136
1403
levomepromazine; oral, parenteral
N05AA02 [21604493]
—
—
—
—
—
—
3.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:13.19%
controls:0.35%
—
—
—
—
—
—
19
5
125
1412
paracetamol; oral, parenteral, rectal
N02BE01 [21604344]
6.3e-01
1.1e+00
1.3e+00
—
—
6.6e-01
7.3e-01
cases:32.26%
controls:20.26%
cases:23.08%
controls:9.49%
cases:7.05%
controls:1.99%
—
—
—
—
cases:18.59%
controls:10.54%
cases:43.75%
controls:27.31%
50
314
105
1236
36
148
120
1412
11
31
145
1529
—
—
29
162
127
1375
63
387
81
1030
hydroxyzine; oral, parenteral
N05BB01 [21604590]
1.7e+00
—
—
—
—
2.0e+00
1.8e+00
cases:7.74%
controls:1.48%
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.46%
cases:7.64%
controls:1.34%
12
23
143
1527
—
—
—
—
5
7
151
1530
11
19
133
1398
Physiotherapist
Z3226 [2001311560]
1.5e+00
2.0e+00
—
—
—
1.7e+00
1.4e+00
cases:7.74%
controls:1.87%
cases:4.49%
controls:0.64%
—
—
—
—
—
—
cases:3.21%
controls:0.59%
cases:6.25%
controls:1.69%
12
29
143
1521
7
10
149
1550
—
—
—
5
9
151
1528
9
24
135
1393
Feeling anxious/nervous/tense
P01 [2002000798]
1.7e+00
—
—
—
—
—
1.6e+00
cases:5.16%
controls:0.97%
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:1.62%
8
15
147
1535
—
—
—
—
—
11
23
133
1394
zolpidem; oral
N05CF02 [21604655]
1.7e+00
1.7e+00
—
—
—
1.4e+00
1.1e+00
cases:9.68%
controls:2.00%
cases:5.13%
controls:1.03%
—
—
—
—
—
—
cases:5.13%
controls:1.30%
cases:8.33%
controls:2.96%
15
31
140
1519
8
16
148
1544
—
—
—
8
20
148
1517
12
42
132
1375
escitalopram; oral
N06AB10 [21604718]
1.8e+00
1.3e+00
—
—
—
1.5e+00
1.0e+00
cases:14.84%
controls:2.84%
cases:5.77%
controls:1.67%
—
—
—
—
—
—
cases:5.77%
controls:1.37%
cases:9.03%
controls:3.53%
23
44
132
1506
9
26
147
1534
—
—
—
9
21
147
1516
13
50
131
1367
Acute bronchitis, unspecified
J20.9 [45562445]
1.7e+00
—
—
—
—
—
1.5e+00
cases:7.10%
controls:1.35%
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:1.62%
11
21
144
1529
—
—
—
—
—
10
23
134
1394
buprenorphine; parenteral, sublingual, transdermal
N02AE01 [21604287]
3.2e+00
—
—
—
—
—
1.5e+00
cases:8.39%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.92%
13
6
142
1544
—
—
—
—
—
6
13
138
1404
salbutamol; inhalant
R03AC02 [21603256]
1.1e+00
1.0e+00
—
—
—
9.0e-01
9.7e-01
cases:22.58%
controls:8.52%
cases:12.18%
controls:4.87%
—
—
—
—
—
—
cases:10.90%
controls:4.75%
cases:28.47%
controls:13.13%
35
132
120
1418
19
76
137
1484
—
—
—
17
73
139
1464
41
186
103
1231
Pain in limb
M79.6 [45587063]
1.1e+00
1.9e+00
-1.0e+50
—
—
1.0e+00
8.8e-01
cases:9.68%
controls:3.55%
cases:8.33%
controls:1.35%
cases:0.00%
controls:0.38%
—
—
—
—
cases:4.49%
controls:1.69%
cases:11.11%
controls:4.94%
15
55
140
1495
13
21
143
1539
0
6
156
1554
—
—
7
26
149
1511
16
70
128
1347
Low back pain
M54.5 [45553207]
1.6e+00
1.6e+00
—
—
—
1.5e+00
1.3e+00
cases:14.19%
controls:3.29%
cases:4.49%
controls:0.90%
—
—
—
—
—
—
cases:4.49%
controls:1.04%
cases:11.81%
controls:3.53%
22
51
133
1499
7
14
149
1546
—
—
—
7
16
149
1521
17
50
127
1367
Physiotherapy
R4110 [2001310233]
1.4e+00
1.2e+00
—
—
—
—
1.3e+00
cases:7.74%
controls:1.94%
cases:4.49%
controls:1.41%
—
—
—
—
—
—
—
—
cases:10.42%
controls:2.96%
12
30
143
1520
7
22
149
1538
—
—
—
—
15
42
129
1375
lamotrigine; oral
N03AX09 [21604431]
1.9e+00
—
—
—
—
—
2.7e+00
cases:3.23%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:9.03%
controls:0.64%
5
8
150
1542
—
—
—
—
—
13
9
131
1408
Moderate depressive episode
F32.1 [45552478]
2.7e+00
—
—
—
—
—
—
cases:4.52%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
7
5
148
1545
—
—
—
—
—
—
Psychological sympt/compl other
P29 [2002000823]
1.9e+00
—
—
—
—
—
2.7e+00
cases:3.87%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:0.56%
6
9
149
1541
—
—
—
—
—
11
8
133
1409
Dysthymia
F34.1 [45586238]
—
—
—
1.0e+50
—
—
2.7e+00
—
—
—
—
—
—
cases:5.13%
controls:0.00%
—
—
—
—
cases:4.86%
controls:0.35%
—
—
—
8
0
148
1560
—
—
7
5
137
1412
vortioxetine; oral
N06AX26 [44819158]
2.1e+00
—
—
—
—
—
2.6e+00
cases:3.23%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.49%
5
6
150
1544
—
—
—
—
—
9
7
135
1410
Other specified counselling
Z71.8 [45581061]
8.1e-01
—
-1.0e+50
—
—
1.5e+00
1.0e+00
cases:4.52%
controls:2.06%
—
—
cases:0.00%
controls:0.32%
—
—
—
—
cases:6.41%
controls:1.43%
cases:11.81%
controls:4.66%
7
32
148
1518
—
0
5
156
1555
—
—
10
22
146
1515
17
66
127
1351
Abdominal pain localized other
D06 [2002000305]
—
-1.0e+50
—
—
—
—
2.5e+00
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.42%
—
0
6
156
1554
—
—
—
—
7
6
137
1411
Moderate depressive episode with somatic syndrome
F32.11 [2000501981]
—
—
—
—
—
—
2.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.42%
—
—
—
—
—
—
7
6
137
1411
carbamazepine; oral, rectal
N03AF01 [21604417]
2.5e+00
—
—
—
—
—
1.8e+00
cases:5.16%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.71%
8
7
147
1543
—
—
—
—
—
6
10
138
1407
Low back symptom/complaint
L03 [2002000628]
1.2e+00
—
—
—
—
2.5e+00
1.1e+00
cases:5.81%
controls:1.87%
—
—
—
—
—
—
—
—
cases:4.49%
controls:0.39%
cases:8.33%
controls:3.03%
9
29
146
1521
—
—
—
—
7
6
149
1531
12
43
132
1374
Observation for suspected disease or condition, unspecified
Z03.9 [45552062]
1.3e+00
—
—
—
—
2.5e+00
6.6e-01
cases:3.23%
controls:0.90%
—
—
—
—
—
—
—
—
cases:4.49%
controls:0.39%
cases:4.17%
controls:2.19%
5
14
150
1536
—
—
—
—
7
6
149
1531
6
31
138
1386
Thorax X-ray examination
GD1AA [2001303617]
1.3e+00
1.3e+00
—
—
—
—
1.1e+00
cases:10.97%
controls:3.16%
cases:5.77%
controls:1.67%
—
—
—
—
—
—
—
—
cases:13.19%
controls:4.66%
17
49
138
1501
9
26
147
1534
—
—
—
—
19
66
125
1351
lactulose; oral
A06AD11 [21600571]
—
1.9e+00
—
—
—
—
2.5e+00
—
—
cases:3.85%
controls:0.58%
—
—
—
—
—
—
—
—
cases:9.72%
controls:0.92%
—
6
9
150
1551
—
—
—
—
14
13
130
1404
Amylase [Enzymatic activity/volume] in Serum or Plasma
1798-8 [3016771]
1.3e+00
—
—
—
—
1.3e+00
1.1e+00
cases:9.03%
controls:2.65%
—
—
—
—
—
—
—
—
cases:3.85%
controls:1.11%
cases:11.81%
controls:4.09%
14
41
141
1509
—
—
—
—
6
17
150
1520
17
58
127
1359
Sodium [Moles/volume] in Serum or Plasma
2951-2 [3019550]
6.9e-01
7.8e-01
1.1e+00
—
1.2e+00
9.1e-01
4.8e-01
cases:23.23%
controls:13.16%
cases:21.15%
controls:10.96%
cases:6.41%
controls:2.18%
—
—
cases:5.77%
controls:1.86%
cases:23.08%
controls:10.80%
cases:38.19%
controls:27.59%
36
204
119
1346
33
171
123
1389
10
34
146
1526
—
9
29
147
1530
36
166
120
1371
55
391
89
1026
Pulmonary Disease
29 [38004472]
1.4e+00
6.2e-01
—
—
—
1.0e+00
9.7e-01
cases:16.13%
controls:4.58%
cases:5.13%
controls:2.82%
—
—
—
—
—
—
cases:7.69%
controls:2.93%
cases:15.28%
controls:6.42%
25
71
130
1479
8
44
148
1516
—
—
—
12
45
144
1492
22
91
122
1326
Depressive episode
F32 [45595904]
2.3e+00
—
—
—
—
—
—
cases:3.87%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
—
—
6
6
149
1544
—
—
—
—
—
—
Psychiatric treatment plan, standard
ICB01 [2001304098]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.49%
—
—
—
—
—
—
7
7
137
1410
Carboxyhemoglobin/Hemoglobin.total in Arterial blood
2030-5 [3028653]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.49%
—
—
—
—
—
—
7
7
137
1410
Other chronic pain
R52.2 [45568139]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.49%
—
—
—
—
—
—
7
7
137
1410
Methemoglobin/Hemoglobin.total in Arterial blood
2615-3 [3006217]
—
—
—
—
—
—
2.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.42%
—
—
—
—
—
—
6
6
138
1411
bisoprolol; oral
C07AB07 [21601689]
1.2e+00
1.1e+00
1.1e+00
—
—
8.1e-01
7.5e-01
cases:15.48%
controls:5.29%
cases:12.18%
controls:4.55%
cases:3.85%
controls:1.28%
—
—
—
—
cases:10.90%
controls:5.14%
cases:16.67%
controls:8.61%
24
82
131
1468
19
71
137
1489
6
20
150
1540
—
—
17
79
139
1458
24
122
120
1295
Hemoglobin [Mass/volume] in Arterial blood
30313-1 [3002173]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.64%
—
—
—
—
—
—
8
9
136
1408
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
R29.8 [45587505]
2.2e+00
—
—
—
—
—
1.5e+00
cases:4.52%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:0.78%
7
8
148
1542
—
—
—
—
—
5
11
139
1406
Other and unspecified abdominal pain
R10.4 [45568113]
1.0e+00
—
—
—
—
1.6e+00
1.2e+00
cases:10.97%
controls:4.19%
—
—
—
—
—
—
—
—
cases:5.13%
controls:1.11%
cases:15.28%
controls:5.36%
17
65
138
1485
—
—
—
—
8
17
148
1520
22
76
122
1341
Extensive abdominal CT
JN3BD [2001305556]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.49%
—
—
—
—
—
—
6
7
138
1410
Fractional oxyhemoglobin in Arterial blood
2714-4 [3014007]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.49%
—
—
—
—
—
—
6
7
138
1410
Methadone [Presence] in Urine by Screen method
19550-3 [3028707]
—
—
—
—
—
—
2.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.49%
—
—
—
—
—
—
6
7
138
1410
Folate [Moles/volume] in Serum or Plasma
14732-2 [3021960]
—
—
—
—
—
2.2e+00
9.1e-01
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.46%
cases:6.25%
controls:2.61%
—
—
—
—
—
6
7
150
1530
9
37
135
1380
Treatment of a patient needing special arrangements
WYA30 [2001310874]
—
—
—
—
—
—
2.1e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.78%
—
—
—
—
—
—
9
11
135
1406
Base excess in Arterial blood by calculation
1925-7 [3003396]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.38%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.71%
—
0
6
156
1554
—
—
—
—
8
10
136
1407
ciprofloxacin; oral, parenteral
J01MA02 [21603009]
1.0e+00
8.4e-01
-1.0e+50
—
—
1.6e+00
1.1e+00
cases:9.68%
controls:3.68%
cases:3.21%
controls:1.41%
cases:0.00%
controls:0.51%
—
—
—
—
cases:4.49%
controls:0.98%
cases:11.81%
controls:4.45%
15
57
140
1493
5
22
151
1538
0
8
156
1552
—
—
7
15
149
1522
17
63
127
1354
Supine thorax X-ray examination
GD1QA [2001303648]
—
-1.0e+50
—
—
—
—
2.1e+00
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.64%
—
0
5
156
1555
—
—
—
—
7
9
137
1408
sitagliptin; oral
A10BH01 [21600784]
—
—
—
—
—
-1.0e+50
2.1e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.59%
cases:4.86%
controls:0.64%
—
—
—
—
—
0
9
156
1528
7
9
137
1408
Hypothyroidism, unspecified
E03.9 [45537945]
2.1e+00
2.0e+00
—
—
—
—
1.2e+00
cases:7.10%
controls:0.97%
cases:3.21%
controls:0.45%
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.98%
11
15
144
1535
5
7
151
1553
—
—
—
—
9
28
135
1389
Malaise and fatigue
R53 [45553741]
2.1e+00
1.5e+00
—
—
—
—
1.1e+00
cases:7.10%
controls:0.97%
cases:3.21%
controls:0.71%
—
—
—
—
—
—
—
—
cases:6.94%
controls:2.33%
11
15
144
1535
5
11
151
1549
—
—
—
—
10
33
134
1384
Psychologist
Z2445 [2001311558]
2.0e+00
—
—
—
—
—
—
cases:3.87%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
—
—
6
8
149
1542
—
—
—
—
—
—
Acute apical periodontitis of pulpal origin
K04.4 [45567286]
—
—
—
—
—
—
2.0e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.56%
—
—
—
—
—
—
6
8
138
1409
Bacteria identified in Blood by Culture
600-7 [3023368]
—
—
—
—
—
2.0e+00
1.1e+00
—
—
—
—
—
—
—
—
—
—
cases:3.85%
controls:0.52%
cases:7.64%
controls:2.61%
—
—
—
—
—
6
8
150
1529
11
37
133
1380
Social worker
Z2446 [2001311559]
2.0e+00
—
—
—
—
—
—
cases:5.16%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
8
11
147
1539
—
—
—
—
—
—
Care involving use of other rehabilitation procedures
Z50.8 [45556842]
2.0e+00
—
—
—
—
—
—
cases:4.52%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
—
—
7
10
148
1540
—
—
—
—
—
—
Right side
ZXA00 [2001311346]
9.8e-01
2.0e+00
—
—
—
—
1.6e-01
cases:5.16%
controls:2.00%
cases:4.49%
controls:0.64%
—
—
—
—
—
—
—
—
cases:3.47%
controls:2.96%
8
31
147
1519
7
10
149
1550
—
—
—
—
5
42
139
1375
Supplier / Service Provider
OMOP5117446 [33004]
-1.1e+00
-5.5e-01
-1.0e+50
—
—
—
3.0e+00
cases:9.68%
controls:24.26%
cases:5.77%
controls:9.62%
cases:0.00%
controls:0.83%
—
—
—
—
—
—
cases:15.28%
controls:0.85%
15
376
140
1174
9
150
147
1410
0
13
156
1547
—
—
—
22
12
122
1405
Person encountering health services in unspecified circumstances
Z76.9 [45609967]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:1.06%
—
—
—
—
—
—
10
15
134
1402
Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma
6768-6 [3035995]
6.9e-01
3.4e-01
—
—
—
9.3e-01
1.0e+00
cases:14.84%
controls:8.06%
cases:8.33%
controls:6.09%
—
—
—
—
—
—
cases:13.46%
controls:5.79%
cases:28.47%
controls:12.70%
23
125
132
1425
13
95
143
1465
—
—
—
21
89
135
1448
41
180
103
1237
Dyspnoea
R06.0 [45558449]
1.9e+00
—
—
—
—
—
1.1e+00
cases:7.10%
controls:1.10%
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:2.75%
11
17
144
1533
—
—
—
—
—
11
39
133
1378
Oxygen saturation in Arterial blood
2708-6 [3016502]
—
-1.0e+50
—
—
—
—
1.9e+00
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.85%
—
0
5
156
1555
—
—
—
—
8
12
136
1405
pH of Arterial blood
2744-1 [3019977]
—
-1.0e+50
—
—
—
—
1.9e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.85%
—
0
7
156
1553
—
—
—
—
8
12
136
1405
Transferrin.carbohydrate deficient.disialo/Transferrin.total in Serum or Plasma
21573-1 [3003031]
1.1e+00
1.9e+00
—
—
—
1.9e+00
1.2e+00
cases:4.52%
controls:1.48%
cases:3.85%
controls:0.58%
—
—
—
—
—
—
cases:5.13%
controls:0.78%
cases:7.64%
controls:2.47%
7
23
148
1527
6
9
150
1551
—
—
—
8
12
148
1525
11
35
133
1382
Orthopedic Surgery
20 [38004465]
9.9e-01
9.8e-01
—
—
—
9.0e-01
9.3e-01
cases:21.29%
controls:9.16%
cases:9.62%
controls:3.85%
—
—
—
—
—
—
cases:10.26%
controls:4.42%
cases:25.69%
controls:12.00%
33
142
122
1408
15
60
141
1500
—
—
—
16
68
140
1469
37
170
107
1247
Drugs identified in Urine by Screen method Nominal
12286-1 [3011288]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:0.99%
—
—
—
—
—
—
9
14
135
1403
Occupational therapy
R4120 [2001310234]
1.9e+00
—
—
—
—
—
—
cases:4.52%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
148
1539
—
—
—
—
—
—
Spinal stenosis
M48.0 [45557888]
1.9e+00
—
—
—
—
—
—
cases:4.52%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
7
11
148
1539
—
—
—
—
—
—
Neck symptom/complaint
L01 [2002000626]
—
—
—
—
—
—
1.9e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.78%
—
—
—
—
—
—
7
11
137
1406
Pain localized to upper abdomen
R10.1 [45568111]
1.9e+00
—
—
—
—
—
1.2e+00
cases:5.16%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.05%
8
13
147
1537
—
—
—
—
—
9
29
135
1388
levofloxacin; inhalant, oral, parenteral
J01MA12 [21603019]
1.9e+00
—
—
—
—
—
7.9e-01
cases:5.16%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:2.26%
8
13
147
1537
—
—
—
—
—
7
32
137
1385
Chloride [Moles/volume] in Serum or Plasma
2075-0 [3014576]
2.1e+00
—
—
—
—
—
1.9e+00
cases:3.23%
controls:0.39%
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:1.27%
5
6
150
1544
—
—
—
—
—
11
18
133
1399
Other specified special examinations
Z01.8 [45581003]
1.8e+00
—
—
—
—
—
5.8e-01
cases:8.39%
controls:1.42%
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:1.98%
13
22
142
1528
—
—
—
—
—
5
28
139
1389
Dizziness and giddiness
R42 [45568132]
1.8e+00
—
—
—
—
-1.0e+50
1.1e+00
cases:5.81%
controls:0.97%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.65%
cases:4.86%
controls:1.62%
9
15
146
1535
—
—
—
—
0
10
156
1527
7
23
137
1394
General Surgery
2 [38004447]
7.4e-01
5.5e-01
—
—
—
1.1e+00
2.6e-01
cases:29.68%
controls:16.77%
cases:8.97%
controls:5.38%
—
—
—
—
—
—
cases:11.54%
controls:4.29%
cases:19.44%
controls:15.67%
46
260
109
1290
14
84
142
1476
—
—
—
18
66
138
1471
28
222
116
1195
Thyroxine (T4) free [Moles/volume] in Serum or Plasma
14920-3 [3008486]
9.1e-01
7.9e-01
—
—
—
8.9e-01
6.2e-01
cases:17.42%
controls:7.81%
cases:12.18%
controls:5.90%
—
—
—
—
—
—
cases:14.10%
controls:6.31%
cases:28.47%
controls:17.64%
27
121
128
1429
19
92
137
1468
—
—
—
22
97
134
1440
41
250
103
1167
One hour or less
ZXE00 [2001311394]
6.4e-01
1.8e+00
—
—
—
9.7e-01
9.2e-01
cases:9.03%
controls:4.97%
cases:8.97%
controls:1.60%
—
—
—
—
—
—
cases:3.21%
controls:1.24%
cases:12.50%
controls:5.36%
14
77
141
1473
14
25
142
1535
—
—
—
5
19
151
1518
18
76
126
1341
melatonin; oral
N05CH01 [21604659]
—
—
—
—
—
1.7e+00
1.8e+00
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.59%
cases:8.33%
controls:1.48%
—
—
—
—
—
5
9
151
1528
12
21
132
1396
Oxygen [Partial pressure] in Arterial blood
2703-7 [3027801]
—
-1.0e+50
—
—
—
—
1.8e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.85%
—
0
7
156
1553
—
—
—
—
7
12
137
1405
Carbon dioxide [Partial pressure] in Arterial blood
2019-8 [3027946]
—
-1.0e+50
—
—
—
—
1.8e+00
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
cases:4.86%
controls:0.85%
—
0
7
156
1553
—
—
—
—
7
12
137
1405
Rheumatology
66 [38004491]
1.2e+00
—
—
—
—
1.8e+00
1.3e+00
cases:4.52%
controls:1.42%
—
—
—
—
—
—
—
—
cases:4.49%
controls:0.78%
cases:5.56%
controls:1.62%
7
22
148
1528
—
—
—
—
7
12
149
1525
8
23
136
1394
Limited function/disability (L)
L28 [2002000647]
—
—
—
—
—
—
1.8e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:0.99%
—
—
—
—
—
—
8
14
136
1403
Osmolality of Urine
2695-5 [3026782]
1.7e+00
1.4e+00
—
—
—
1.7e+00
1.1e+00
cases:5.16%
controls:0.97%
cases:4.49%
controls:1.09%
—
—
—
—
—
—
cases:3.21%
controls:0.59%
cases:8.33%
controls:2.89%
8
15
147
1535
7
17
149
1543
—
—
—
5
9
151
1528
12
41
132
1376
Bacteria [Presence] in Urine
87829-8 [36304419]
1.7e+00
1.3e+00
—
—
—
1.4e+00
7.3e-01
cases:5.16%
controls:0.97%
cases:3.85%
controls:1.09%
—
—
—
—
—
—
cases:3.21%
controls:0.85%
cases:6.94%
controls:3.46%
8
15
147
1535
6
17
150
1543
—
—
—
5
13
151
1524
10
49
134
1368
Abdominal pain/cramps general
D01 [2002000300]
—
—
—
—
—
-1.0e+50
1.7e+00
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
cases:6.25%
controls:1.20%
—
—
—
—
—
0
6
156
1531
9
17
135
1400
Therapeutic discussion
SPAT1240 [2001700341]
8.2e-01
—
—
—
—
1.4e+00
1.7e+00
cases:3.87%
controls:1.74%
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.78%
cases:9.03%
controls:1.83%
6
27
149
1523
—
—
—
—
5
12
151
1525
13
26
131
1391
Carpal tunnel syndrome
G56.0 [45566891]
1.7e+00
—
—
—
—
—
—
cases:5.16%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
—
—
8
16
147
1534
—
—
—
—
—
—
Potassium [Moles/volume] in Serum or Plasma
2823-3 [3023103]
6.7e-01
7.7e-01
1.1e+00
—
1.1e+00
8.7e-01
4.6e-01
cases:23.23%
controls:13.35%
cases:21.15%
controls:11.09%
cases:6.41%
controls:2.24%
—
—
cases:5.77%
controls:1.92%
cases:23.08%
controls:11.19%
cases:38.19%
controls:28.02%
36
207
119
1343
33
173
123
1387
10
35
146
1525
—
9
30
147
1529
36
172
120
1365
55
397
89
1020
Neurosurgery
14 [38004459]
1.6e+00
1.5e+00
—
—
—
—
—
cases:6.45%
controls:1.35%
cases:3.85%
controls:0.90%
—
—
—
—
—
—
—
—
—
—
10
21
145
1529
6
14
150
1546
—
—
—
—
—
Magnesium [Moles/volume] in Serum or Plasma
2601-3 [3012095]
—
—
—
—
—
—
1.6e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:7.64%
controls:1.62%
—
—
—
—
—
—
11
23
133
1394
Headache
R51.80 [2000503603]
1.6e+00
2.3e+00
—
—
—
—
1.0e+00
cases:5.81%
controls:1.23%
cases:3.21%
controls:0.32%
—
—
—
—
—
—
—
—
cases:4.86%
controls:1.76%
9
19
146
1531
5
5
151
1555
—
—
—
—
7
25
137
1392
cefalexin; oral
J01DB01 [21602870]
6.5e-01
9.1e-01
—
—
—
5.8e-01
4.6e-01
cases:40.00%
controls:25.74%
cases:16.67%
controls:7.44%
—
—
—
—
—
—
cases:13.46%
controls:8.00%
cases:41.67%
controls:31.12%
62
399
93
1151
26
116
130
1444
—
—
—
21
123
135
1414
60
441
84
976
propranolol; oral, parenteral
C07AA05 [21601670]
9.1e-01
1.6e+00
—
—
—
1.1e+00
9.0e-01
cases:8.39%
controls:3.55%
cases:6.41%
controls:1.41%
—
—
—
—
—
—
cases:4.49%
controls:1.56%
cases:10.42%
controls:4.52%
13
55
142
1495
10
22
146
1538
—
—
—
7
24
149
1513
15
64
129
1353
Skin symptom/complaint other
S29 [2002000993]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.41%
—
—
—
—
—
—
9
20
135
1397
tamsulosin; oral
G04CA02 [21602669]
1.5e+00
—
—
—
-1.0e+50
1.1e+00
2.4e-01
cases:6.45%
controls:1.48%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:4.49%
controls:1.50%
cases:4.17%
controls:3.32%
10
23
145
1527
—
—
—
0
7
156
1552
7
23
149
1514
6
47
138
1370
Leukocytes [#/volume] in Urine
30405-5 [3018095]
1.5e+00
9.0e-01
—
—
—
1.0e+00
6.8e-01
cases:5.81%
controls:1.35%
cases:3.85%
controls:1.60%
—
—
—
—
—
—
cases:3.85%
controls:1.43%
cases:9.72%
controls:5.15%
9
21
146
1529
6
25
150
1535
—
—
—
6
22
150
1515
14
73
130
1344
Cardiology
6 [38004451]
1.5e+00
9.0e-01
—
—
—
—
7.5e-01
cases:12.26%
controls:3.03%
cases:3.85%
controls:1.60%
—
—
—
—
—
—
—
—
cases:11.11%
controls:5.58%
19
47
136
1503
6
25
150
1535
—
—
—
—
16
79
128
1338
Hand/finger symptom/complaint
L12 [2002000636]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:1.48%
—
—
—
—
—
—
9
21
135
1396
calcium (different salts in combination); oral
A12AA20 [21600872]
1.5e+00
6.1e-01
-1.0e+50
—
—
—
6.7e-01
cases:10.32%
controls:2.58%
cases:4.49%
controls:2.50%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
cases:8.33%
controls:4.45%
16
40
139
1510
7
39
149
1521
0
12
156
1548
—
—
—
12
63
132
1354
Esophagoscopy, gastroscopy and duodenoscopy
UJD10 [2001304788]
1.1e+00
—
—
—
—
—
1.5e+00
cases:7.74%
controls:2.77%
—
—
—
—
—
—
—
—
—
—
cases:10.42%
controls:2.61%
12
43
143
1507
—
—
—
—
—
15
37
129
1380
Inpatient Visit
IP [9201]
7.3e-01
—
—
—
—
—
1.4e+00
cases:7.10%
controls:3.55%
—
—
—
—
—
—
—
—
—
—
cases:10.42%
controls:2.68%
11
55
144
1495
—
—
—
—
—
15
38
129
1379
salmeterol and fluticasone
R03AK06 [21603280]
1.4e+00
1.3e+00
—
—
—
1.2e+00
7.3e-01
cases:6.45%
controls:1.61%
cases:4.49%
controls:1.22%
—
—
—
—
—
—
cases:3.85%
controls:1.24%
cases:4.86%
controls:2.40%
10
25
145
1525
7
19
149
1541
—
—
—
6
19
150
1518
7
34
137
1383
Chest pain, unspecified
R07.4 [45558450]
1.1e+00
1.5e+00
—
—
—
—
1.4e+00
cases:5.16%
controls:1.81%
cases:3.21%
controls:0.77%
—
—
—
—
—
—
—
—
cases:11.81%
controls:3.11%
8
28
147
1522
5
12
151
1548
—
—
—
—
17
44
127
1373
Creatine kinase [Enzymatic activity/volume] in Serum or Plasma
2157-6 [3007220]
8.3e-01
1.4e+00
—
—
—
—
1.4e+00
cases:5.16%
controls:2.32%
cases:4.49%
controls:1.09%
—
—
—
—
—
—
—
—
cases:11.81%
controls:3.32%
8
36
147
1514
7
17
149
1543
—
—
—
—
17
47
127
1370
omeprazole; oral, parenteral
A02BC01 [21600096]
1.3e+00
1.0e+00
-1.0e+50
—
—
1.0e+00
8.5e-01
cases:9.03%
controls:2.52%
cases:3.21%
controls:1.15%
cases:0.00%
controls:0.38%
—
—
—
—
cases:4.49%
controls:1.63%
cases:8.33%
controls:3.74%
14
39
141
1511
5
18
151
1542
0
6
156
1554
—
—
7
25
149
1512
12
53
132
1364
Pain in joint
M25.5 [45586941]
1.3e+00
1.1e+00
—
—
—
1.4e+00
7.8e-01
cases:7.74%
controls:2.19%
cases:3.85%
controls:1.28%
—
—
—
—
—
—
cases:3.85%
controls:0.98%
cases:7.64%
controls:3.67%
12
34
143
1516
6
20
150
1540
—
—
—
6
15
150
1522
11
52
133
1365
Bilirubin.total [Moles/volume] in Serum or Plasma
14631-6 [3006140]
8.5e-01
2.3e-01
—
—
—
1.1e+00
1.3e+00
cases:10.32%
controls:4.71%
cases:4.49%
controls:3.59%
—
—
—
—
—
—
cases:7.69%
controls:2.80%
cases:20.14%
controls:6.42%
16
73
139
1477
7
56
149
1504
—
—
—
12
43
144
1494
29
91
115
1326
Cathetrisation of vein
TPH04 [2001309597]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.47%
—
—
—
—
—
—
12
35
132
1382
montelukast; oral
R03DC03 [21603356]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:8.33%
controls:2.47%
—
—
—
—
—
—
12
35
132
1382
Calcium.ionized [Moles/volume] in Serum or Plasma
1995-0 [3021347]
1.1e+00
7.8e-01
—
—
—
1.2e+00
1.3e+00
cases:8.39%
controls:3.03%
cases:4.49%
controls:2.12%
—
—
—
—
—
—
cases:5.13%
controls:1.56%
cases:15.28%
controls:4.87%
13
47
142
1503
7
33
149
1527
—
—
—
8
24
148
1513
22
69
122
1348
Type 2 diabetes mellitus, without complications
E11.9 [45561952]
9.8e-01
1.1e+00
—
—
—
1.0e+00
1.2e+00
cases:5.81%
controls:2.26%
cases:4.49%
controls:1.60%
—
—
—
—
—
—
cases:5.13%
controls:1.89%
cases:11.81%
controls:3.74%
9
35
146
1515
7
25
149
1535
—
—
—
8
29
148
1508
17
53
127
1364
Removal of sutures
SPAT1153 [2001700254]
6.6e-01
1.7e+00
—
—
—
—
1.2e+00
cases:4.52%
controls:2.39%
cases:3.21%
controls:0.58%
—
—
—
—
—
—
—
—
cases:11.11%
controls:3.53%
7
37
148
1513
5
9
151
1551
—
—
—
—
16
50
128
1367
Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma
19072-8 [3016431]
8.7e-01
9.8e-01
—
—
—
1.1e+00
1.2e+00
cases:8.39%
controls:3.68%
cases:5.77%
controls:2.24%
—
—
—
—
—
—
cases:5.77%
controls:2.02%
cases:18.06%
controls:6.28%
13
57
142
1493
9
35
147
1525
—
—
—
9
31
147
1506
26
89
118
1328
Gastroenterology
10 [38004455]
3.7e-01
8.7e-01
—
—
—
7.4e-01
1.2e+00
cases:4.52%
controls:3.16%
cases:4.49%
controls:1.92%
—
—
—
—
—
—
cases:3.21%
controls:1.56%
cases:11.11%
controls:3.67%
7
49
148
1501
7
30
149
1530
—
—
—
5
24
151
1513
16
52
128
1365
Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma
48065-7 [3051714]
7.9e-01
—
—
—
—
—
1.2e+00
cases:3.23%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:9.03%
controls:2.96%
5
23
150
1527
—
—
—
—
—
13
42
131
1375
Differential panel, method unspecified - Blood
69738-3 [42870588]
7.9e-01
—
—
—
—
—
1.2e+00
cases:5.81%
controls:2.71%
—
—
—
—
—
—
—
—
—
—
cases:13.19%
controls:4.59%
9
42
146
1508
—
—
—
—
—
19
65
125
1352
etoricoxib; oral
M01AH05 [21603996]
4.8e-01
1.1e+00
—
—
—
6.1e-01
5.6e-02
cases:12.90%
controls:8.39%
cases:8.33%
controls:2.82%
—
—
—
—
—
—
cases:6.41%
controls:3.58%
cases:13.19%
controls:12.56%
20
130
135
1420
13
44
143
1516
—
—
—
10
55
146
1482
19
178
125
1239
Diabetes non-insulin dependent
T90 [2002001131]
7.5e-01
—
—
—
—
6.9e-01
1.1e+00
cases:4.52%
controls:2.19%
—
—
—
—
—
—
—
—
cases:3.21%
controls:1.63%
cases:9.03%
controls:3.11%
7
34
148
1516
—
—
—
—
5
25
151
1512
13
44
131
1373
Medical doctor
Z2221 [2001311556]
1.1e+00
1.1e+00
—
—
-1.0e+50
1.1e+00
6.5e-01
cases:10.32%
controls:3.61%
cases:3.85%
controls:1.35%
—
—
—
—
cases:0.00%
controls:0.58%
cases:3.21%
controls:1.11%
cases:5.56%
controls:2.96%
16
56
139
1494
6
21
150
1539
—
—
0
9
156
1550
5
17
151
1520
8
42
136
1375
Bacteria [#/volume] in Urine by Automated count
51480-2 [3031040]
8.7e-01
6.7e-01
—
—
—
1.1e+00
5.8e-01
cases:12.26%
controls:5.55%
cases:7.69%
controls:4.10%
—
—
—
—
—
—
cases:9.62%
controls:3.38%
cases:18.06%
controls:11.01%
19
86
136
1464
12
64
144
1496
—
—
—
15
52
141
1485
26
156
118
1261
atorvastatin; oral
C10AA05 [21601860]
6.1e-01
9.4e-01
-1.0e+50
—
—
1.1e+00
6.0e-01
cases:6.45%
controls:3.61%
cases:7.69%
controls:3.14%
cases:0.00%
controls:0.58%
—
—
—
—
cases:9.62%
controls:3.38%
cases:12.50%
controls:7.27%
10
56
145
1494
12
49
144
1511
0
9
156
1551
—
—
15
52
141
1485
18
103
126
1314
Person consulting for explanation of investigation findings
Z71.2 [45552100]
9.4e-01
—
—
—
—
—
1.1e+00
cases:4.52%
controls:1.81%
—
—
—
—
—
—
—
—
—
—
cases:9.72%
controls:3.53%
7
28
148
1522
—
—
—
—
—
14
50
130
1367
More than one and less than three hours
ZXE10 [2001311401]
1.1e+00
7.9e-01
—
—
—
—
1.0e+00
cases:9.03%
controls:3.29%
cases:3.21%
controls:1.47%
—
—
—
—
—
—
—
—
cases:8.33%
controls:3.18%
14
51
141
1499
5
23
151
1537
—
—
—
—
12
45
132
1372
Laceration/cut
S18 [2002000983]
6.3e-01
—
—
—
—
1.4e+00
1.1e+00
cases:6.45%
controls:3.55%
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.78%
cases:11.81%
controls:4.45%
10
55
145
1495
—
—
—
—
5
12
151
1525
17
63
127
1354
betamethasone
A07EA04 [21600656]
1.0e+00
8.3e-01
—
—
—
6.0e-01
3.8e-01
cases:12.90%
controls:4.97%
cases:5.13%
controls:2.31%
—
—
—
—
—
—
cases:3.85%
controls:2.15%
cases:9.03%
controls:6.35%
20
77
135
1473
8
36
148
1524
—
—
—
6
33
150
1504
13
90
131
1327
betamethasone
S02BA07 [21605169]
1.0e+00
8.3e-01
—
—
—
6.0e-01
3.8e-01
cases:12.90%
controls:4.97%
cases:5.13%
controls:2.31%
—
—
—
—
—
—
cases:3.85%
controls:2.15%
cases:9.03%
controls:6.35%
20
77
135
1473
8
36
148
1524
—
—
—
6
33
150
1504
13
90
131
1327
betamethasone
C05AA05 [21601610]
1.0e+00
8.3e-01
—
—
—
6.0e-01
3.8e-01
cases:12.90%
controls:4.97%
cases:5.13%
controls:2.31%
—
—
—
—
—
—
cases:3.85%
controls:2.15%
cases:9.03%
controls:6.35%
20
77
135
1473
8
36
148
1524
—
—
—
6
33
150
1504
13
90
131
1327
betamethasone
D07AC01 [21602120]
1.0e+00
8.3e-01
—
—
—
6.0e-01
3.8e-01
cases:12.90%
controls:4.97%
cases:5.13%
controls:2.31%
—
—
—
—
—
—
cases:3.85%
controls:2.15%
cases:9.03%
controls:6.35%
20
77
135
1473
8
36
148
1524
—
—
—
6
33
150
1504
13
90
131
1327
metformin; oral
A10BA02 [21600747]
7.9e-01
8.2e-01
—
—
—
7.6e-01
1.0e+00
cases:9.68%
controls:4.65%
cases:8.97%
controls:4.17%
—
—
—
—
—
—
cases:8.97%
controls:4.42%
cases:15.28%
controls:6.00%
15
72
140
1478
14
65
142
1495
—
—
—
14
68
142
1469
22
85
122
1332
Otolaryngology
4 [38004449]
1.0e+00
9.8e-01
—
—
—
1.1e+00
6.7e-01
cases:20.00%
controls:8.13%
cases:5.77%
controls:2.24%
—
—
—
—
—
—
cases:7.69%
controls:2.73%
cases:16.67%
controls:9.24%
31
126
124
1424
9
35
147
1525
—
—
—
12
42
144
1495
24
131
120
1286
INR in Blood by Coagulation assay
34714-6 [3032080]
8.1e-01
8.4e-01
—
—
-1.0e+50
1.1e+00
1.0e+00
cases:7.10%
controls:3.29%
cases:4.49%
controls:1.99%
—
—
—
—
cases:0.00%
controls:0.77%
cases:5.77%
controls:2.02%
cases:13.19%
controls:5.22%
11
51
144
1499
7
31
149
1529
—
—
0
12
156
1547
9
31
147
1506
19
74
125
1343
Intramuscular and subcutaneous injection
SPAT1256 [2001700357]
5.7e-01
—
—
—
-1.0e+50
5.8e-01
1.0e+00
cases:6.45%
controls:3.74%
—
—
—
—
—
—
cases:0.00%
controls:0.45%
cases:3.21%
controls:1.82%
cases:14.58%
controls:5.86%
10
58
145
1492
—
—
—
0
7
156
1552
5
28
151
1509
21
83
123
1334
Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma
2324-2 [3026910]
7.3e-01
6.7e-01
—
—
2.0e+00
9.6e-01
5.6e-01
cases:14.19%
controls:7.35%
cases:8.97%
controls:4.81%
—
—
—
—
cases:3.21%
controls:0.45%
cases:11.54%
controls:4.75%
cases:22.22%
controls:13.97%
22
114
133
1436
14
75
142
1485
—
—
5
7
151
1552
18
73
138
1464
32
198
112
1219
prednisolone; oral, parenteral
H02AB06 [21602734]
9.6e-01
6.9e-01
-1.0e+50
—
—
9.5e-01
4.2e-01
cases:13.55%
controls:5.68%
cases:6.41%
controls:3.33%
cases:0.00%
controls:0.45%
—
—
—
—
cases:7.05%
controls:2.86%
cases:11.81%
controls:8.12%
21
88
134
1462
10
52
146
1508
0
7
156
1553
—
—
11
44
145
1493
17
115
127
1302
cetirizine; oral
R06AE07 [21603497]
8.1e-01
8.6e-01
—
—
—
7.5e-01
9.5e-01
cases:14.84%
controls:7.16%
cases:6.41%
controls:2.82%
—
—
—
—
—
—
cases:6.41%
controls:3.12%
cases:17.36%
controls:7.48%
23
111
132
1439
10
44
146
1516
—
—
—
10
48
146
1489
25
106
119
1311
prednisolone
A07EA01 [21600653]
9.4e-01
6.7e-01
-1.0e+50
—
—
9.5e-01
4.2e-01
cases:13.55%
controls:5.74%
cases:6.41%
controls:3.40%
cases:0.00%
controls:0.45%
—
—
—
—
cases:7.05%
controls:2.86%
cases:11.81%
controls:8.12%
21
89
134
1461
10
53
146
1507
0
7
156
1553
—
—
11
44
145
1493
17
115
127
1302
hydrocortisone butyrate
D07AB02 [21602106]
9.3e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.81%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
90
134
1460
6
27
150
1533
—
—
—
—
22
109
122
1308
hydrocortisone
D07AA02 [21602102]
9.3e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.81%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
90
134
1460
6
27
150
1533
—
—
—
—
22
109
122
1308
hydrocortisone buteprate
D07AB11 [21602115]
9.3e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.81%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
90
134
1460
6
27
150
1533
—
—
—
—
22
109
122
1308
hydrocortisone aceponate
D07AC16 [21602135]
9.3e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.81%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
90
134
1460
6
27
150
1533
—
—
—
—
22
109
122
1308
25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Moles/volume] in Serum or Plasma
68438-1 [40771025]
-1.7e-01
—
—
—
—
1.4e+00
9.2e-01
cases:3.23%
controls:3.81%
—
—
—
—
—
—
—
—
cases:5.77%
controls:1.50%
cases:15.28%
controls:6.70%
5
59
150
1491
—
—
—
—
9
23
147
1514
22
95
122
1322
hydrocortisone
C05AA01 [21601608]
9.1e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.94%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
92
134
1458
6
27
150
1533
—
—
—
—
22
109
122
1308
hydrocortisone
A07EA02 [21600654]
9.1e-01
8.2e-01
—
—
—
—
7.7e-01
cases:13.55%
controls:5.94%
cases:3.85%
controls:1.73%
—
—
—
—
—
—
—
—
cases:15.28%
controls:7.69%
21
92
134
1458
6
27
150
1533
—
—
—
—
22
109
122
1308
esomeprazole; oral, parenteral
A02BC05 [21600100]
9.1e-01
7.2e-01
—
—
-1.0e+50
9.4e-01
7.3e-01
cases:13.55%
controls:5.94%
cases:5.13%
controls:2.56%
—
—
—
—
cases:0.00%
controls:0.58%
cases:6.41%
controls:2.60%
cases:11.81%
controls:6.07%
21
92
134
1458
8
40
148
1520
—
—
0
9
156
1550
10
40
146
1497
17
86
127
1331
Erythrocyte sedimentation rate [Velocity] in Red Blood Cells by Westergren method
4537-7 [3013707]
8.8e-01
6.6e-01
—
—
—
7.4e-01
5.0e-01
cases:16.13%
controls:7.42%
cases:9.62%
controls:5.19%
—
—
—
—
—
—
cases:8.97%
controls:4.49%
cases:22.22%
controls:14.82%
25
115
130
1435
15
81
141
1479
—
—
—
14
69
142
1468
32
210
112
1207
Intraoral radiographic dental examination
EB1AA [2001301903]
8.7e-01
7.9e-01
—
—
—
6.6e-01
5.8e-01
cases:18.06%
controls:8.45%
cases:6.41%
controls:3.01%
—
—
—
—
—
—
cases:5.77%
controls:3.06%
cases:18.75%
controls:11.43%
28
131
127
1419
10
47
146
1513
—
—
—
9
47
147
1490
27
162
117
1255
Ferritin [Mass/volume] in Serum or Plasma
2276-4 [3001122]
4.3e-01
8.1e-01
-1.0e+50
—
—
3.1e-01
8.1e-01
cases:5.81%
controls:3.87%
cases:4.49%
controls:2.05%
cases:0.00%
controls:0.38%
—
—
—
—
cases:3.85%
controls:2.86%
cases:18.06%
controls:8.89%
9
60
146
1490
7
32
149
1528
0
6
156
1554
—
—
6
44
150
1493
26
126
118
1291
Thyrotropin [Units/volume] in Serum or Plasma
3016-3 [3009201]
6.5e-01
7.6e-01
1.2e+00
—
—
7.9e-01
5.7e-01
cases:18.71%
controls:10.71%
cases:15.38%
controls:7.82%
cases:3.21%
controls:1.03%
—
—
—
—
cases:17.31%
controls:8.65%
cases:34.72%
controls:23.15%
29
166
126
1384
24
122
132
1438
5
16
151
1544
—
—
27
133
129
1404
50
328
94
1089
Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI)/1.73 sq M
62238-1 [40764999]
4.0e-01
5.5e-01
1.1e+00
—
1.1e+00
7.7e-01
4.8e-01
cases:13.55%
controls:9.48%
cases:13.46%
controls:8.21%
cases:4.49%
controls:1.54%
—
—
cases:4.49%
controls:1.54%
cases:17.95%
controls:9.17%
cases:31.25%
controls:21.88%
21
147
134
1403
21
128
135
1432
7
24
149
1536
—
7
24
149
1535
28
141
128
1396
45
310
99
1107
Creatinine [Moles/volume] in Serum or Plasma
14682-9 [3020564]
4.9e-01
6.2e-01
9.3e-01
—
1.0e+00
7.1e-01
4.2e-01
cases:23.23%
controls:15.68%
cases:22.44%
controls:13.46%
cases:6.41%
controls:2.63%
—
—
cases:7.05%
controls:2.63%
cases:25.00%
controls:14.12%
cases:40.97%
controls:31.26%
36
243
119
1307
35
210
121
1350
10
41
146
1519
—
11
41
145
1518
39
217
117
1320
59
443
85
974
Telehealth
OMOP5556618 [722455]
4.0e-01
7.2e-01
1.1e+00
—
1.1e+00
7.5e-01
7.0e-01
cases:20.65%
controls:14.90%
cases:13.46%
controls:7.05%
cases:4.49%
controls:1.54%
—
—
cases:3.85%
controls:1.35%
cases:14.10%
controls:7.22%
cases:32.64%
controls:19.41%
32
231
123
1319
21
110
135
1450
7
24
149
1536
—
6
21
150
1538
22
111
134
1426
47
275
97
1142
Enduring personality change, unspecified
F62.9 [45586250]
—
—
—
1.0e+50
1.0e+50
1.0e+50
1.0e+50
—
—
—
—
—
—
cases:32.05%
controls:0.00%
cases:5.13%
controls:0.00%
cases:12.18%
controls:0.00%
cases:6.94%
controls:0.00%
—
—
—
50
0
106
1560
8
0
148
1559
19
0
137
1537
10
0
134
1417
ganirelix; parenteral
H01CC01 [21602720]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
7
144
1410
Albumin [Mass/time] in Urine collected for unspecified duration
49002-9 [3050449]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.20%
—
—
—
—
—
—
0
17
144
1400
Hemoglobin [Presence] in Urine by Test strip
5794-3 [3011397]
—
—
—
—
—
—
5.2e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:4.23%
—
—
—
—
—
—
10
60
134
1357
Urate [Moles/volume] in Serum or Plasma
14933-6 [3026493]
1.2e+00
—
—
—
—
-1.0e+50
4.4e-01
cases:5.16%
controls:1.68%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.91%
cases:4.86%
controls:3.18%
8
26
147
1524
—
—
—
—
0
14
156
1523
7
45
137
1372
Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection
20444-6 [3028369]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
5
144
1412
insulins and analogues for injection, intermediate-acting - combinations; parenteral
A10AC30 [21600727]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
—
—
—
—
—
0
11
156
1526
—
ibuprofen; oral, parenteral, rectal
M01AE01 [21603967]
4.3e-01
6.3e-01
1.2e+00
—
4.3e-01
5.5e-01
3.9e-01
cases:42.58%
controls:32.58%
cases:24.36%
controls:14.68%
cases:6.41%
controls:2.12%
—
—
cases:3.21%
controls:2.12%
cases:21.15%
controls:13.40%
cases:46.53%
controls:37.12%
66
505
89
1045
38
229
118
1331
10
33
146
1527
—
5
33
151
1526
33
206
123
1331
67
526
77
891
Vertigo/dizziness
N17 [2002000728]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
5
156
1532
—
sumatriptan; nasal, oral, parenteral, rectal
N02CC01 [21604376]
-1.4e-01
4.9e-01
—
—
—
—
3.3e-01
cases:3.23%
controls:3.68%
cases:3.21%
controls:1.99%
—
—
—
—
—
—
—
—
cases:4.17%
controls:3.03%
5
57
150
1493
5
31
151
1529
—
—
—
—
6
43
138
1374
combinations of corticosteroids
D07AB30 [21602118]
6.7e-01
4.6e-01
—
—
-1.0e+50
7.5e-01
6.7e-01
cases:16.77%
controls:9.35%
cases:4.49%
controls:2.88%
—
—
—
—
cases:0.00%
controls:0.32%
cases:5.77%
controls:2.80%
cases:15.97%
controls:8.89%
26
145
129
1405
7
45
149
1515
—
—
0
5
156
1554
9
43
147
1494
23
126
121
1291
Polyneuropathy, unspecified
G62.9 [45566898]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
—
—
—
—
—
—
—
0
5
156
1532
—
SMOKING - SMOKE2: no - SMOKE3: never - SMOKE5: never
SMOKING-2-3-5 [2002330114]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:4.65%
—
—
—
—
—
—
—
—
—
—
—
—
0
72
155
1478
—
—
—
—
—
—
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
281 [2001600213]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
5
144
1412
Ophthalmology
18 [38004463]
2.0e-01
5.0e-01
—
—
—
3.8e-01
1.6e-01
cases:10.97%
controls:9.16%
cases:7.69%
controls:4.81%
—
—
—
—
—
—
cases:6.41%
controls:4.49%
cases:14.58%
controls:12.70%
17
142
138
1408
12
75
144
1485
—
—
—
10
69
146
1468
21
180
123
1237
Dysuria
R30.0 [45592416]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
6
144
1411
Hand and fingers X-ray examination
ND2AA [2001307607]
1.7e+00
—
—
—
—
—
—
cases:3.87%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
—
—
6
11
149
1539
—
—
—
—
—
—
chloramphenicol
G01AA05 [21602367]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.84%
—
—
—
—
—
—
—
—
—
—
—
—
0
13
155
1537
—
—
—
—
—
—
Asthma
J45 [45596282]
1.5e+00
—
—
—
—
—
1.1e+00
cases:4.52%
controls:1.03%
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:1.98%
7
16
148
1534
—
—
—
—
—
8
28
136
1389
Malignant tumor of the upper outer quadrant of the mammary gland, ductal tumor
C50.41 [2000501002]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.39%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.64%
0
6
155
1544
0
5
156
1555
—
—
—
0
5
156
1532
0
9
144
1408
Ultrasound examination of pregnancy (at 12. week of gestaion or later) including basic examination of fetus
MA2AE [2001306829]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:2.06%
cases:0.00%
controls:0.77%
—
—
—
—
—
—
cases:0.00%
controls:0.72%
—
—
0
32
155
1518
0
12
156
1548
—
—
—
0
11
156
1526
—
Testosterone [Moles/volume] in Serum or Plasma
14913-8 [3017446]
—
—
—
—
—
—
1.2e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:1.34%
—
—
—
—
—
—
6
19
138
1398
metoclopramide; oral, parenteral, rectal
A03FA01 [21600484]
7.5e-01
—
—
—
—
1.3e+00
6.9e-01
cases:5.81%
controls:2.84%
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.91%
cases:6.25%
controls:3.25%
9
44
146
1506
—
—
—
—
5
14
151
1523
9
46
135
1371
Occupatioal Medicine
901 [44777713]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
6
144
1411
tranexamic acid; oral, parenteral
B02AA02 [21601036]
5.6e-01
—
—
—
—
—
1.1e+00
cases:3.23%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:1.48%
5
29
150
1521
—
—
—
—
—
6
21
138
1396
Glucose [Moles/volume] in Serum or Plasma
14749-6 [3013826]
9.0e-01
1.0e+00
—
—
—
6.4e-01
7.6e-01
cases:9.68%
controls:4.19%
cases:8.33%
controls:3.14%
—
—
—
—
—
—
cases:4.49%
controls:2.41%
cases:16.67%
controls:8.54%
15
65
140
1485
13
49
143
1511
—
—
—
7
37
149
1500
24
121
120
1296
Seborrhoeic keratosis
L82 [45548208]
—
-1.0e+50
—
—
—
-1.0e+50
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
—
0
9
156
1551
—
—
—
0
6
156
1531
—
Migraine
G43 [45566873]
-1.0e+50
—
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.39%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.39%
—
—
0
6
155
1544
—
—
—
—
0
6
156
1531
—
Lipid panel - Serum or Plasma
100898-6 [1761868]
-3.2e-01
2.8e-01
—
—
-1.0e+50
—
1.2e-01
cases:3.23%
controls:4.39%
cases:3.21%
controls:2.44%
—
—
—
—
cases:0.00%
controls:0.32%
—
—
cases:10.42%
controls:9.39%
5
68
150
1482
5
38
151
1522
—
—
0
5
156
1554
—
15
133
129
1284
Antenatal screening
243787009 [4087235]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
0
5
155
1545
—
—
—
—
—
0
5
144
1412
Nonorganic insomnia
F51.0 [45552492]
—
—
—
—
—
2.0e+00
8.9e-01
—
—
—
—
—
—
—
—
—
—
cases:3.21%
controls:0.46%
cases:4.86%
controls:2.05%
—
—
—
—
—
5
7
151
1530
7
29
137
1388
Sprain and strain of ankle
S93.4 [45550848]
—
—
—
—
—
—
8.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:1.48%
—
—
—
—
—
—
5
21
139
1396
Pollen allergy UNS
J30.19 [2000502595]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.56%
—
—
—
—
—
—
0
8
144
1409
Cardiovascular sympt/complt other
K29 [2002000556]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
5
144
1412
Counselling and guidance related to occupational health
SPAT1311 [2001700412]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.35%
—
—
—
—
—
—
0
5
144
1412
Choriogonadotropin [Units/volume] in Urine
25372-4 [3023511]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
7
144
1410
ABO and Rh group [Type] in Blood by Confirmatory method
77397-8 [46236098]
—
-1.0e+50
—
—
—
—
2.7e-01
—
—
cases:0.00%
controls:1.28%
—
—
—
—
—
—
—
—
cases:3.47%
controls:2.68%
—
0
20
156
1540
—
—
—
—
5
38
139
1379
Respiratory and circulatory monitoring
WX700 [2001310817]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
7
156
1553
—
—
—
—
—
Infiltrating duct carcinoma, NOS, of breast, NOS
8500/3-C50.9 [44505315]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
—
0
7
155
1543
—
—
—
—
—
—
Premature rupture of membranes, unspecified
O42.9 [45558306]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
7
144
1410
Spontaneous abortion, Incomplete, without complication
O03.4 [45558185]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
155
1545
—
—
—
—
—
—
Carcinoembryonic Ag [Mass/volume] in Serum or Plasma
2039-6 [3003785]
-1.0e+50
-1.0e+50
—
—
—
-1.0e+50
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.58%
—
—
—
—
—
—
cases:0.00%
controls:0.59%
—
—
0
5
155
1545
0
9
156
1551
—
—
—
0
9
156
1528
—
Hand Surgery
40 [38004480]
1.0e+00
—
—
—
—
—
6.9e-01
cases:5.16%
controls:1.87%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:3.25%
8
29
147
1521
—
—
—
—
—
9
46
135
1371
Extensive structural and functional ultrasound examination of heart
FM1EE [2001303307]
—
—
—
—
—
—
4.1e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:2.33%
—
—
—
—
—
—
5
33
139
1384
Cocaine [Presence] in Urine
3397-7 [3016879]
—
—
—
—
—
—
1.4e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.86%
controls:1.27%
—
—
—
—
—
—
7
18
137
1399
Necrosis of pulp
K04.1 [45572186]
-1.0e+50
—
—
—
—
—
1.3e+00
cases:0.00%
controls:0.65%
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:1.20%
0
10
155
1540
—
—
—
—
—
6
17
138
1400
tiaprofenic acid; oral, rectal
M01AE11 [21603977]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
—
0
5
155
1545
—
—
—
—
—
—
valaciclovir; oral
J05AB11 [21603137]
—
—
—
—
—
—
8.8e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:1.76%
—
—
—
—
—
—
6
25
138
1392
Excessive and frequent menstruation with irregular cycle
N92.1 [45539073]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.52%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
8
155
1542
—
—
—
—
—
0
7
144
1410
cough suppressants and expectorants
R05FB02 [21603442]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
7
156
1553
—
—
—
—
—
Bacteria identified in Skin by Aerobe culture
620-5 [3007853]
—
-1.0e+50
—
—
—
—
1.4e+00
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
—
—
cases:4.86%
controls:1.27%
—
0
10
156
1550
—
—
—
—
7
18
137
1399
cefadroxil; oral
J01DB05 [21602874]
4.4e-01
-1.0e+50
—
—
—
—
—
cases:3.87%
controls:2.52%
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
6
39
149
1511
0
7
156
1553
—
—
—
—
—
fluticasone furoate
R03BA09 [45893496]
1.3e+00
—
—
—
—
—
9.7e-01
cases:5.16%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
cases:6.25%
controls:2.47%
8
23
147
1527
—
—
—
—
—
9
35
135
1382
Audiometric test
21727005 [4071702]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
—
—
—
0
5
156
1555
—
—
—
—
—
More than three and less than five hours
ZXE20 [2001311408]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.45%
—
—
—
—
—
—
—
—
—
—
—
0
7
156
1553
—
—
—
—
—
Fasting glucose [Moles/volume] in Serum or Plasma
14771-0 [3018251]
4.9e-01
5.0e-01
—
—
1.4e+00
7.1e-01
4.0e-01
cases:17.42%
controls:11.42%
cases:11.54%
controls:7.31%
—
—
—
—
cases:3.21%
controls:0.83%
cases:14.10%
controls:7.48%
cases:31.94%
controls:23.99%
27
177
128
1373
18
114
138
1446
—
—
5
13
151
1546
22
115
134
1422
46
340
98
1077
Other ultrasound examination during pregnancy
SPAT1189 [2001700290]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
—
—
—
—
—
—
0
7
144
1410
Erysipelas
A46 [45561706]
—
—
—
—
—
—
1.5e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:0.92%
—
—
—
—
—
—
6
13
138
1404
Colonoscopy Study observation
28023-0 [3022145]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.16%
—
—
—
—
—
—
—
—
—
—
—
—
0
18
155
1532
—
—
—
—
—
—
CBC W Ordered Manual Differential panel - Blood
57782-5 [40760892]
5.5e-01
8.4e-01
—
—
—
6.5e-01
6.9e-01
cases:4.52%
controls:2.65%
cases:3.21%
controls:1.41%
—
—
—
—
—
—
cases:3.21%
controls:1.69%
cases:9.03%
controls:4.73%
7
41
148
1509
5
22
151
1538
—
—
—
5
26
151
1511
13
67
131
1350
paracetamol, combinations excl. psycholeptics
N02BE51 [21604348]
6.7e-01
—
—
—
—
—
7.0e-02
cases:6.45%
controls:3.42%
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:3.25%
10
53
145
1497
—
—
—
—
—
5
46
139
1371
Treatment-related counselling outside office
SPAT1249 [2001700350]
7.1e-01
9.8e-01
-1.0e+50
—
—
—
4.6e-01
cases:12.26%
controls:6.45%
cases:5.77%
controls:2.24%
cases:0.00%
controls:0.51%
—
—
—
—
—
—
cases:12.50%
controls:8.26%
19
100
136
1450
9
35
147
1525
0
8
156
1552
—
—
—
18
117
126
1300
dexamethasone and antiinfectives
S03CA01 [21605206]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
—
—
0
23
155
1527
—
—
—
—
—
—
Hematocrit [Volume Fraction] of Blood by calculation
20570-8 [3009542]
2.2e-01
4.2e-01
7.5e-01
—
7.1e-01
3.5e-01
2.7e-01
cases:22.58%
controls:19.03%
cases:23.72%
controls:16.99%
cases:7.05%
controls:3.46%
—
—
cases:6.41%
controls:3.27%
cases:23.08%
controls:17.50%
cases:43.06%
controls:36.49%
35
295
120
1255
37
265
119
1295
11
54
145
1506
—
10
51
146
1508
36
269
120
1268
62
517
82
900
valsartan; oral
C09CA03 [21601826]
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:1.04%
—
—
—
—
—
—
—
0
16
156
1521
—
Panorama tomography of teeth and jaws or similar X-ray examination
EB1HA [2001301913]
2.2e-01
—
—
—
—
—
6.4e-01
cases:5.16%
controls:4.19%
—
—
—
—
—
—
—
—
—
—
cases:10.42%
controls:5.79%
8
65
147
1485
—
—
—
—
—
15
82
129
1335
Hemoglobin [Mass/volume] in Blood
718-7 [3000963]
2.2e-01
4.1e-01
7.5e-01
—
7.1e-01
3.5e-01
2.7e-01
cases:22.58%
controls:19.03%
cases:23.72%
controls:17.12%
cases:7.05%
controls:3.46%
—
—
cases:6.41%
controls:3.27%
cases:23.08%
controls:17.50%
cases:43.06%
controls:36.63%
35
295
120
1255
37
267
119
1293
11
54
145
1506
—
10
51
146
1508
36
269
120
1268
62
519
82
898
Uncompl labour/delivery livebirth
W90 [2002001277]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
6
144
1411
Albumin [Mass/volume] in Urine
1754-1 [3012516]
1.1e+00
7.9e-01
—
—
—
3.2e-01
4.4e-01
cases:5.81%
controls:2.00%
cases:3.21%
controls:1.47%
—
—
—
—
—
—
cases:3.21%
controls:2.34%
cases:9.03%
controls:6.00%
9
31
146
1519
5
23
151
1537
—
—
—
5
36
151
1501
13
85
131
1332
Leukocyte esterase [Presence] in Urine by Automated test strip
60026-2 [40763086]
2.0e-01
8.7e-01
—
—
—
5.4e-01
4.1e-01
cases:5.16%
controls:4.26%
cases:5.77%
controls:2.50%
—
—
—
—
—
—
cases:3.85%
controls:2.28%
cases:11.81%
controls:8.19%
8
66
147
1484
9
39
147
1521
—
—
—
6
35
150
1502
17
116
127
1301
Additional procedure necessary for restorative treatment
SFC01 [2001310369]
9.0e-01
—
—
—
—
—
6.7e-01
cases:5.81%
controls:2.45%
—
—
—
—
—
—
—
—
—
—
cases:6.94%
controls:3.67%
9
38
146
1512
—
—
—
—
—
10
52
134
1365
tolfenamic acid; oral, rectal
M01AG02 [21603988]
9.8e-01
—
—
—
—
—
—
cases:3.87%
controls:1.48%
—
—
—
—
—
—
—
—
—
—
—
—
6
23
149
1527
—
—
—
—
—
—
Attendant Care Provider
3747A0650X [38004431]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
6
144
1411
Calprotectin [Mass/mass] in Stool
38445-3 [3048689]
—
-1.0e+50
—
—
-1.0e+50
-1.0e+50
—
—
—
cases:0.00%
controls:1.15%
—
—
—
—
cases:0.00%
controls:0.32%
cases:0.00%
controls:0.46%
—
—
—
0
18
156
1542
—
—
0
5
156
1554
0
7
156
1530
—
Bacteria identified in Isolate by Culture
43409-2 [3042936]
—
—
—
—
—
—
9.7e-01
—
—
—
—
—
—
—
—
—
—
—
—
cases:3.47%
controls:1.34%
—
—
—
—
—
—
5
19
139
1398
nystatin; vaginal
G01AA01 [21602363]
-1.0e+50
-1.0e+50
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.45%
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.49%
0
7
155
1543
0
5
156
1555
—
—
—
—
0
7
144
1410
tetanus toxoid, combinations with diphtheria toxoid
J07AM51 [21601317]
—
-1.0e+50
—
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
0
9
156
1551
—
—
—
—
—
Other and unspecified ovarian cysts
N83.2 [45539066]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.92%
—
—
—
—
—
—
0
13
144
1404
Urinalysis macro (dipstick) panel - Urine
24357-6 [3037467]
5.1e-01
5.3e-01
—
—
—
1.0e+00
5.0e-01
cases:9.68%
controls:6.06%
cases:7.05%
controls:4.29%
—
—
—
—
—
—
cases:9.62%
controls:3.77%
cases:20.14%
controls:13.27%
15
94
140
1456
11
67
145
1493
—
—
—
15
58
141
1479
29
188
115
1229
Blasts/Leukocytes in Blood
26446-5 [3025159]
—
—
—
—
—
—
1.3e+00
—
—
—
—
—
—
—
—
—
—
—
—
cases:4.17%
controls:1.13%
—
—
—
—
—
—
6
16
138
1401
Anogenital (venereal) warts
A63.0 [45585929]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.64%
—
—
—
—
—
—
0
9
144
1408
verapamil; oral, parenteral
C08DA01 [21601767]
-1.0e+50
—
—
—
—
-1.0e+50
-1.0e+50
cases:0.00%
controls:0.32%
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.33%
cases:0.00%
controls:0.42%
0
5
155
1545
—
—
—
—
0
5
156
1532
0
6
144
1411
Other chest pain
R07.3 [45597166]
1.7e+00
—
—
—
—
—
—
cases:3.23%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
5
9
150
1541
—
—
—
—
—
—
chlorhexidine, combinations
D08AC52 [21602208]
6.5e-01
—
—
—
—
—
8.4e-01
cases:3.87%
controls:2.06%
—
—
—
—
—
—
—
—
—
—
cases:5.56%
controls:2.47%
6
32
149
1518
—
—
—
—
—
8
35
136
1382
Nontoxic multinodular goitre
E04.2 [45576425]
—
—
—
—
—
—
-1.0e+50
—
—
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.42%
—
—
—
—
—
—
0
6
144
1411
Bone marrow biopsy
XW000 [2001310618]
-1.0e+50
—
—
—
—
—
—
cases:0.00%
controls:0.58%
—
—
—
—
—
—
—
—
—
—
—
—
0
9
155
1541
—
—
—
—
—
—
scopolamine
A04AD01 [21600499]
-1.0e+50
—
—
—
—
—
-1.0e+50
cases:0.00%
controls:0.71%
—
—
—
—
—
—
—
—
—
—
cases:0.00%
controls:0.99%
0
11
155
1539
—
—
—
—
—
0
14
144
1403

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
28
35
9.52
21.61
2.6
1.5
—
—
—
0
0
28
76
4.27
9.67
3.5
1.5
—
—
—
0
0
28
77
4.21
9.50
3.6
1.5
—
—
—
0
0
28
80
4.04
9.01
3.6
1.5
—
—
—
0
0
28
80
4.04
9.01
3.5
1.5
—
—
—
0
0
97
577
2.78
8.82
9.9
7.9
1.21
1.21
mmol/l
0.04
89
507
49
205
3.02
8.72
2.2
1.7
395.40
65363569.80
pmol/l
0.50
43
179
90
522
2.70
8.51
10.0
7.3
1.20
1.21
mmol/l
0.50
85
501
27
81
3.82
8.09
3.7
1.5
—
—
—
0
0
34
121
3.31
7.88
16.1
11.8
7.40
7.42
ph
0.86
15
69
86
505
2.55
7.68
2.2
2.0
97.93
96.70
pmol/l
0.08
54
272
33
121
3.19
7.26
16.8
11.7
5.45
5.17
kpa
1.16
33
115
33
121
3.19
7.26
16.7
11.7
10.61
13.09
kpa
2.19
33
116
26
85
3.47
6.84
2.7
1.4
0.39
0.31
mg/l
0.32
13
35
73
422
2.36
6.45
3.9
3.2
7.17
8.43
mmol/l
1.14
62
369
59
316
2.39
6.14
4.6
3.6
1.02
1.02
kg/l
1.45
39
203
11
12
9.75
5.89
15.3
12.1
0.75
0.63
mmol/l
0.56
11
12
9
7
13.53
5.65
1.7
1.0
—
—
—
0
0
58
322
2.27
5.45
4.8
2.6
—
—
—
0
0
70
425
2.17
5.24
2.3
3.3
2.35
2.36
mmol/l
0.66
65
396
54
298
2.24
5.10
2.5
2.1
2.87
2.62
mg/l
0.32
46
260
29
121
2.71
5.00
5.6
5.4
0.00
0.07
%
—
6
29
127
995
2.45
4.76
8.7
8.4
81.52
76.59
u/l
0.59
122
952
14
33
4.55
4.45
3.8
2.8
23.47
24.70
mmol/l
0.56
14
33
60
363
2.06
4.38
3.5
2.9
0.43
0.29
e6/l
0.31
41
261
34
164
2.37
4.33
17.0
7.0
104.85
104.24
mmol/l
0.50
34
164
18
63
3.10
4.22
4.8
12.2
—
—
—
0
0
129
1040
2.35
4.16
6.6
4.2
14.43
14.51
pmol/l
0.12
121
981
22
88
2.74
4.09
2.4
3.7
66.38
72.11
e9/l
0.43
14
63
67
430
1.97
4.09
3.8
3.0
17.14
46.72
e6/l
1.07
50
328
99
726
1.98
4.09
7.3
7.0
2.00
1.92
e9/l
0.32
89
644
25
108
2.56
4.01
19.5
8.1
—
—
—
0
0
27
122
2.47
3.95
5.0
5.1
0.33
0.83
%
—
6
36
99
731
1.96
3.95
7.9
7.4
0.22
0.19
e9/l
0.52
85
645
34
173
2.23
3.81
2.6
2.1
—
—
—
0
0
56
345
1.97
3.80
4.1
4.4
7.40
7.40
ph
0.16
36
247
26
118
2.44
3.76
4.9
5.1
0.17
0.78
%
—
6
32
79
551
1.87
3.65
28.2
11.0
1.17
1.14
inr
0.21
68
443
38
207
2.10
3.59
2.5
2.7
3.98
2.11
e6/l
0.60
14
101
95
707
1.87
3.54
7.4
7.0
0.04
0.04
e9/l
0.02
83
616
14
47
3.17
3.51
2.0
2.7
—
—
—
0
0
52
322
1.92
3.42
6.0
4.2
—
—
—
0
0
59
383
1.87
3.35
4.0
4.0
2.27
8.84
mg/mmol
2.89
36
239
94
705
1.83
3.34
7.5
7.0
0.57
0.56
e9/l
0.24
83
617
11
29
4.00
3.25
3.7
2.8
8.65
8.52
kpa
0.10
11
29
25
120
2.29
3.20
3.4
4.4
7.37
7.38
ph
0.58
16
70
72
505
1.79
3.14
4.9
3.6
33.54
48.88
e6/l
0.23
49
347
65
445
1.79
3.06
6.0
6.6
—
—
—
0
0
9
21
4.48
3.04
4.3
2.9
92.47
89.95
%
—
9
21
95
732
1.75
2.92
4.9
3.5
0.00
0.00
estimate
-0.00
25
143
96
743
1.75
2.89
4.9
3.5
0.04
0.00
estimate
0.49
25
143
0
74
0.00
2.86
0.0
1.1
—
0.88
—
0
74
67
472
1.73
2.80
5.3
3.4
23.73
51.44
ng/l
1.10
47
286
86
651
1.71
2.76
7.1
6.9
0.61
0.69
%
0.80
80
618
86
652
1.71
2.74
7.0
6.8
3.02
2.82
%
0.32
80
621
16
67
2.55
2.73
2.5
4.0
24.38
24.09
mmol/l
0.22
16
67
46
293
1.81
2.70
2.0
1.9
0.81
1.07
mg/l
0.44
35
225
17
74
2.45
2.69
3.2
2.8
0.75
0.65
%
0.60
17
74
0
71
0.00
2.65
0.0
1.1
—
0.66
—
0
9
56
381
1.73
2.62
3.6
3.3
11.62
61.66
mg/l
3.80
33
238
17
75
2.42
2.62
3.2
2.9
1.85
1.09
%
0.92
17
75
29
161
1.98
2.57
2.2
1.4
—
—
—
0
0
95
748
1.68
2.56
4.9
3.6
0.00
0.00
estimate
-0.00
23
137
111
913
1.74
2.52
5.1
4.0
—
—
—
0
0
85
654
1.65
2.47
7.2
6.9
8.49
8.64
%
0.18
79
629
90
705
1.65
2.42
6.9
7.0
8.98
11.29
umol/l
3.11
82
682
7
17
4.26
2.39
6.0
3.6
17.77
15.84
%
—
7
17
47
315
1.70
2.28
2.7
2.1
—
—
—
0
0
97
783
1.62
2.24
9.9
10.5
4.40
3.90
e9/l
0.98
85
685
10
36
2.90
2.18
1.3
1.1
—
—
—
0
0
78
604
1.58
2.10
5.2
3.2
6.24
6.11
ph
0.51
45
360
6
15
4.11
2.06
1.5
1.4
—
—
—
0
0
5
11
4.65
1.95
32.0
20.5
691.20
858.64
nmol/l
—
5
11
53
383
1.58
1.88
5.1
3.7
0.00
0.00
estimate
-0.00
24
135
6
17
3.63
1.85
1.0
1.5
18.50
17.21
ng/l
—
6
17
138
1247
1.88
1.83
7.8
5.0
1.80
1.86
mu/l
0.26
130
1174
22
126
1.87
1.79
2.5
2.8
46.53
29.27
u/l
0.30
15
103
6
18
3.42
1.76
2.2
1.2
—
—
—
0
0
5
13
3.93
1.73
2.2
1.4
90.36
90.18
%
—
5
13
12
55
2.28
1.72
8.8
4.8
37.07
36.97
°c
0.69
12
55
15
77
2.05
1.65
21.3
7.9
25.67
24.87
mmol/l
0.60
15
77
6
20
3.08
1.59
1.8
1.2
—
—
—
0
0
82
671
1.46
1.56
4.0
3.0
88.50
96.21
ug/l
0.16
75
643
11
51
2.24
1.54
1.2
2.7
21.00
19.91
s
0.48
11
45
29
189
1.66
1.54
2.0
1.7
—
—
—
0
0
5
15
3.41
1.53
1.0
2.2
—
—
—
0
0
20
118
1.80
1.50
3.8
2.7
10.72
10.55
g/l
0.07
20
107
28
183
1.65
1.47
1.4
1.3
—
—
—
0
0
75
609
1.44
1.46
16.2
11.2
0.00
0.00
e9/l
0.50
61
495
52
395
1.47
1.42
6.7
5.9
—
—
—
0
0
7
29
2.48
1.41
5.3
2.7
7.43
7.41
ph
—
7
29
0
38
0.00
1.36
0.0
1.5
—
—
—
0
0
13
69
1.96
1.33
1.8
1.7
—
2904.95
u/l
—
0
22
24
155
1.65
1.33
1.5
1.6
—
—
—
0
0
50
633
0.69
1.33
3.3
3.0
—
—
—
0
0
6
24
2.56
1.31
1.2
1.0
—
—
—
0
0
5
18
2.83
1.29
11.4
3.6
—
—
—
0
0
16
93
1.80
1.27
3.4
1.8
1.01
1.44
g/l
0.75
16
86
54
423
1.42
1.24
2.2
2.3
—
—
—
0
0
29
200
1.55
1.24
1.8
1.4
213.33
500.44
titre
—
6
45
8
37
2.22
1.23
1.0
1.9
—
—
—
0
0
5
19
2.68
1.22
6.8
2.2
4.96
5.00
kpa
—
5
19
5
19
2.68
1.22
6.8
2.2
8.42
8.85
kpa
—
5
19
5
20
2.55
1.16
5.2
2.1
3.36
2.27
u/ml
—
5
20
9
46
2.01
1.05
2.7
13.5
0.77
0.91
%
—
9
40
5
22
2.31
1.04
1.2
2.2
—
—
—
0
0
45
352
1.39
1.03
1.4
1.4
0.79
1.64
u/ml
—
10
103
35
263
1.43
1.00
1.8
1.7
—
—
—
0
0
19
125
1.59
0.99
1.8
1.6
—
—
—
0
0
9
51
1.81
0.96
3.2
12.2
1.83
1.54
%
—
9
45
7
37
1.93
0.95
12.6
9.0
—
—
—
0
0
5
101
0.48
0.93
1.2
1.1
—
—
—
0
0
33
426
0.71
0.92
1.4
1.5
—
—
—
0
0
6
29
2.11
0.90
4.8
4.4
—
—
—
0
0
23
163
1.48
0.88
2.3
3.1
3.39
6.58
umol/l
2.25
18
150
17
113
1.57
0.86
1.4
1.9
0.00
0.00
estimate
—
6
25
6
31
1.97
0.85
1.7
4.4
52.85
60.54
%
—
6
31
11
65
1.74
0.85
1.4
3.2
—
—
—
0
0
6
107
0.54
0.75
1.3
1.4
—
—
—
0
0
30
231
1.37
0.75
3.6
3.3
38.57
336.23
ng/l
1.20
21
155
5
24
2.12
0.75
1.4
1.8
—
—
—
0
0
5
24
2.12
0.75
1.0
1.2
—
—
—
0
0
16
110
1.51
0.71
1.8
1.2
69.63
160.38
u/ml
2.29
16
102
5
26
1.95
0.71
6.0
4.1
3.00
4.54
e9/l
—
5
26
12
178
0.65
0.70
1.1
1.5
—
—
—
0
0
40
328
1.29
0.66
2.3
1.4
2.47
2.30
g/l
0.21
24
208
65
568
1.25
0.64
5.6
3.4
0.00
0.01
estimate
0.50
19
128
0
22
0.00
0.60
0.0
3.4
—
18.52
—
0
22
17
124
1.42
0.58
1.2
1.2
—
—
—
0
0
10
65
1.58
0.57
2.9
1.9
39.00
37.15
nmol/l
—
10
65
14
101
1.42
0.51
2.1
1.7
20.79
24.89
iu/l
—
8
85
17
221
0.74
0.50
1.2
1.5
—
—
—
0
0
141
1360
1.36
0.50
21.8
13.4
24.28
22.23
mg/l
0.27
122
1074
41
350
1.23
0.49
8.6
5.5
—
—
—
0
0
13
176
0.72
0.49
1.5
1.2
—
—
—
0
0
8
56
1.45
0.43
1.5
1.3
—
—
—
0
0
14
105
1.37
0.43
5.1
3.6
—
—
—
0
0
5
32
1.58
0.42
1.0
1.2
—
—
—
0
0
5
32
1.58
0.42
5.8
3.8
48.40
59.22
%
—
5
32
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
—
—
0
0
7
102
0.67
0.41
1.9
1.6
—
—
—
0
0
0
19
0.00
0.39
0.0
1.0
—
—
—
0
0
68
624
1.16
0.36
2.5
2.7
—
—
estimate
—
0
0
12
91
1.35
0.35
1.2
1.1
—
—
—
0
0
6
88
0.67
0.34
1.0
1.1
—
—
—
0
0
22
186
1.21
0.30
2.4
1.8
—
—
—
0
0
118
1222
0.86
0.30
27.2
16.8
331.85
333.38
g/l
0.87
118
1215
32
286
1.15
0.24
1.4
1.3
91.70
28.86
iu/ml
—
10
87
125
1284
0.87
0.24
4.6
4.1
1.57
1.27
mmol/l
3.57
120
1203
5
38
1.33
0.23
1.4
2.4
—
—
—
0
0
0
11
0.00
0.21
0.0
5.5
—
—
—
0
0
0
11
0.00
0.21
0.0
1.4
—
72.82
—
0
11
12
144
0.82
0.21
1.1
1.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.0
—
—
—
0
0
46
429
1.10
0.18
4.9
3.0
0.00
0.01
estimate
0.50
17
121
133
1349
0.91
0.11
5.1
4.7
1.34
1.46
mmol/l
2.45
128
1274
61
586
1.07
0.11
2.0
1.9
1.75
1.41
mmol/l
1.18
49
512
25
267
0.92
0.09
2.8
2.6
0.43
0.71
ug/l
2.25
18
143
6
53
1.14
0.09
1.2
1.8
—
—
—
0
0
9
86
1.05
0.07
1.2
1.2
—
—
—
0
0
27
260
1.05
0.03
1.3
1.3
1.31
6.79
u/ml
1.55
11
103
141
1404
1.04
0.00
19.3
11.7
—
—
—
0
0
54
537
1.01
0.00
2.0
1.9
—
—
—
0
0
137
1365
1.03
0.00
5.6
5.2
2.73
2.78
mmol/l
0.30
132
1291
0
5
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.8
—
28.17
—
0
6
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
149
1487
1.04
-0.00
33.2
20.6
30.15
30.32
pg
0.48
149
1477
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
149
1488
1.03
-0.00
33.9
20.8
136.97
137.74
g/l
0.27
149
1480
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
82
0.97
-0.00
1.4
1.1
—
6.20
—
0
5
0
5
0.00
-0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.5
—
58.83
—
0
6
149
1487
1.04
-0.00
35.7
21.0
41.23
41.14
%
0.10
149
1476
0
8
0.00
-0.00
0.0
1.8
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
149
1487
1.04
-0.00
33.2
20.6
90.80
90.71
fl
0.08
149
1478

Mortality – FinRegistry

↥

Association

Association between endpoint F5_PERSOCHANGE and mortality.

Females

Parameter HR [95% CI] p-value
F5_PERSOCHANGE 3.327 [2.45, 4.53] < 0.001
Birth year 0.992 [0.98, 1.0] 0.089

During the follow-up period (1.1.1998 — 31.12.2019), 74 out of 515 females with F5_PERSOCHANGE died.

Males

Parameter HR [95% CI] p-value
F5_PERSOCHANGE 2.806 [2.0, 3.94] < 0.001
Birth year 0.989 [0.98, 1.0] 0.016

During the follow-up period (1.1.1998 — 31.12.2019), 114 out of 545 males with F5_PERSOCHANGE died.

Mortality risk

Mortality risk for people of age

years, who have F5_PERSOCHANGE.

N-year risk Females Males
1 0.292% 0.583%
5 1.694% 3.167%
10 4.18% 7.849%
15 7.833% 15.454%
20 14.019% 26.046%

Relationships between endpoints

↥

Index endpoint: F5_PERSOCHANGE – Enduring personality changes

GWS hits: -

Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
loading spinner Loading data